View Filing Data

Print Document View Excel Document

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2019	Mar. 26, 2020	Jun. 30, 2019
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Trading Symbol	ECOR
Entity Registrant Name	electroCore, Inc.
Entity Central Index Key	0001560258
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock Shares Outstanding		29,959,565
Entity Public Float			$ 45,501,518
Entity File Number	001-38538
Entity Tax Identification Number	20-3454976
Entity Address, Address Line One	150 Allen Road
Entity Address, Address Line Two	Suite 201
Entity Address, City or Town	Basking Ridge
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07920
City Area Code	973
Local Phone Number	290-0097
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, Par Value $0.001 Per Share
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Annual Report	true
Document Transition Report	false
Documents Incorporated by Reference	Portions of the Registrant’s Definitive Proxy Statement relating to the 2020 Annual Meeting of Stockholders, which will be filed with the Securities Exchange Commission within 120 days after the end of the Registrant’s fiscal year ended December 31, 2019, are incorporated by reference into Part III of this Report.

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 13,563,791	$ 7,600,284
Marketable securities	10,495,350	60,963,087
Accounts receivable	496,140	267,599
Inventories, net	890,992	1,949,402
Prepaid expenses and other current assets	1,087,111	1,918,164
Total current assets	26,533,384	72,698,536
Inventories, noncurrent	6,020,180
Property and equipment, net	345,236	380,904
Operating lease right of use assets	1,430,641
Other assets	1,132,238	424,896
Total assets	35,461,679	73,504,336
Current liabilities:
Accounts payable	5,208,979	2,698,902
Accrued expenses	3,337,379	4,374,101
Note payable	111,878
Current portion of operating lease liability	486,445
Total current liabilities	9,144,681	7,073,003
Deferred rent		245,632
Operating lease liabilities	1,419,880
Total liabilities	10,564,561	7,318,635
Commitments and contingencies (Note 20)
Common Stock, par value $0.001 per share; 500,000,000 shares authorized at December 31, 2019 and December 31, 2018; 29,835,183 shares issued and outstanding at December 31, 2019, and 29,450,035 shares issued and outstanding at December 31, 2018	29,835	29,450
Additional paid-in capital	107,752,066	103,791,013
Accumulated deficit	(83,479,098)	(38,331,215)
Accumulated other comprehensive (loss)/income	(41,295)	60,843
Total stockholders' equity	24,261,508	65,550,091
Noncontrolling interest	635,610	635,610
Total equity	24,897,118	66,185,701
Total liabilities and stockholders' equity	$ 35,461,679	$ 73,504,336

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	29,835,183	29,450,035
Common stock, shares outstanding	29,835,183	29,450,035

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Net sales	$ 2,390,279	$ 992,953
Cost of goods sold	1,156,957	578,743
Gross profit	1,233,322	414,210
Operating expenses:
Research and development	9,902,254	12,466,172
Selling, general and administrative	35,422,301	42,501,562
Restructuring and other severance related charges	1,997,292
Total operating expenses	47,321,847	54,967,734
Loss from operations	(46,088,525)	(54,553,524)
Other (income)/expense
Change in fair value of warrant liability		1,870,923
Interest and other income, net	(970,594)	(1,006,332)
Other expense	12,253	344,909
Total other (income)/expense	(958,341)	1,209,500
Loss before income taxes	(45,130,184)	(55,763,024)
Provision for income taxes	17,699	2,431
Net loss from operations	(45,147,883)	(55,765,455)
Less: Net income attributable to noncontrolling interest		55,005
Net loss attributable to Electrocore subsidiaries and affiliate	$ (45,147,883)	$ (55,820,460)
Net loss per share of common stock - Basic and Diluted (see Note 13)	$ (1.54)	$ (1.19)
Weighted average and potential common shares outstanding - Basic and Diluted (see Note 13)	29,379,975	29,261,943
Electrocore, LLC
Other (income)/expense
Net loss from operations		$ (21,063,332)
Net loss attributable to Electrocore subsidiaries and affiliate		(21,118,337)
ElectroCore, Inc
Other (income)/expense
Net loss from operations		(34,702,123)
Net loss attributable to Electrocore subsidiaries and affiliate	$ (45,147,883)	$ (34,702,123)
Net loss per share of common stock - Basic and Diluted (see Note 13)		$ 1.19

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
Consolidated Statements of Comprehensive Loss - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Net loss from operations	$ (45,147,883)	$ (55,765,455)
Other comprehensive (loss) income:
Foreign currency translation adjustment	(145,418)	3,259
Amount reclassed from accumulated other comprehensive loss		11,024
Unrealized gain(loss) on marketable securities, net of taxes as applicable	43,280	(33,653)
Other comprehensive loss	(102,138)	(19,370)
Comprehensive loss	(45,250,021)	(55,784,825)
Less: Comprehensive income attributable to noncontrolling interest		5,085
Comprehensive loss attributable to Electrocore LLC and electroCore, Inc., subsidiaries and affiliates	(45,250,021)	(55,789,910)
Electrocore, LLC
Net loss from operations		(21,063,332)
Other comprehensive (loss) income:
Comprehensive loss attributable to Electrocore LLC and electroCore, Inc., subsidiaries and affiliates		(21,118,056)
ElectroCore, Inc
Net loss from operations		(34,702,123)
Other comprehensive (loss) income:
Comprehensive loss attributable to Electrocore LLC and electroCore, Inc., subsidiaries and affiliates	$ (45,250,021)	$ (34,671,854)

Consolidated Statements of Changes in Stockholders' Equity and Members' Deficit - USD ($)	Total	Electrocore, LLC	ElectroCore, Inc	Conversion of Series A Preferred Units	Conversion of Series B Preferred Units	Series A Preferred Units	Series A Preferred Units Conversion of Series A Preferred Units	Series B Preferred Units	Series B Preferred Units Conversion of Series B Preferred Units	Common Units	Common Units Conversion of Member Common Units	Common Stock	Common Stock Conversion of Series A Preferred Units	Common Stock Conversion of Series B Preferred Units	Common Stock Conversion of Member Common Units	Common Stock Series A Preferred Units	Common Stock Series B Preferred Units	Common Stock Common Units	Common Stock Profits Interests	Additional Paid-in Capital	Additional Paid-in Capital Conversion of Series A Preferred Units	Additional Paid-in Capital Conversion of Series B Preferred Units	Additional Paid-in Capital Conversion of Member Common Units	Accumulated Deficit	Accumulated Deficit Electrocore, LLC	Accumulated Deficit ElectroCore, Inc	Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss) Electrocore, LLC	(Deficit)/Equity attributable to Electrocore LLC and electroCore, Inc. subsidiaries and affiliate	(Deficit)/Equity attributable to Electrocore LLC and electroCore, Inc. subsidiaries and affiliate Electrocore, LLC	(Deficit)/Equity attributable to Electrocore LLC and electroCore, Inc. subsidiaries and affiliate ElectroCore, Inc	(Deficit)/Equity attributable to Electrocore LLC and electroCore, Inc. subsidiaries and affiliate Conversion of Series A Preferred Units	(Deficit)/Equity attributable to Electrocore LLC and electroCore, Inc. subsidiaries and affiliate Conversion of Series B Preferred Units	Noncontrolling Interest	Noncontrolling Interest Electrocore, LLC
Balances, beginning of period at Dec. 31, 2017	$ (89,467,556)									$ 40,180,619										$ 22,596,485				$ (152,928,928)			$ 80,213		$ (90,071,611)					$ 604,055
Convertible Preferred Units, beginning of period, shares at Dec. 31, 2017						70,918,506		105,186,020
Convertible Preferred Units Value, beginning of period at Dec. 31, 2017						$ 53,518,463		$ 68,755,544
Common Units, beginning of period, shares at Dec. 31, 2017										218,982,140
Net loss	(55,765,455)	$ (21,063,332)	$ (34,702,123)																						$ (21,118,337)	$ (34,702,123)		$ (5,085)		$ (21,123,422)	$ (34,702,123)				$ 60,090
Reclass of accumulated deficit to APIC																				(174,047,265)				174,047,265
Other comprehensive income	(19,370)																										(14,285)		(14,285)					(5,085)
Conversion of units to common stock	1,345			$ 53,518,463	$ 68,755,544				$ (68,755,544)		$ (40,180,619)		$ 3,940	$ 5,844	$ 12,099				$ 1,345		$ 53,514,523	$ 68,749,700	$ 40,168,520						1,345			$ 53,518,463	$ 68,755,544
Temporary equity conversion of units to common stock, shares							(70,918,506)		(105,186,020)
Temporary equity conversion of units to common stock							$ (53,518,463)
Conversion of units to common stock, shares											(218,982,140)		3,939,917	5,843,668	12,099,280				1,345,231
Stock dividend issued to Series A preferred holders												$ 242								3,628,850				(3,629,092)
Stock dividend issued to Series A preferred holders, shares												241,939
Common stock issued related to initial public offering	89,698,655											$ 5,980								89,692,675									89,698,655
Common stock issued related to initial public offering, shares												5,980,000
Issuance costs related to initial public offering	(12,222,438)																			(12,222,438)									(12,222,438)
Reclass of warrant liability to equity	4,110,467																			4,110,467									4,110,467
Noncontrolling interest distributions	(23,450)																																	(23,450)
Stock and Unit-based compensation	7,599,496																			7,599,496									7,599,496
Balances, end of period at Dec. 31, 2018	$ 66,185,701											$ 29,450								103,791,013				(38,331,215)			60,843		65,550,091					635,610
Balances, end of period, shares at Dec. 31, 2018	29,450,035											29,450,035
Convertible Preferred Units Value, beginning of period at Jun. 20, 2018						$ 54,923,430
Conversion of units to common stock, shares												23,470,035				4,181,856	5,843,668	12,099,280	1,345,231
Balances, end of period at Dec. 31, 2019	$ 24,897,118
Balances, end of period, shares at Dec. 31, 2019	29,835,183											29,835,183
Balances, end of period at Dec. 31, 2019	$ 24,897,118											$ 29,835								107,752,066				(83,479,098)			(41,295)		24,261,508					635,610
Common Stock, beginning of period, shares at Dec. 31, 2018	29,450,035											29,450,035
Net loss	$ (45,147,883)																							(45,147,883)					(45,147,883)
Other comprehensive income	(102,138)																										(102,138)		(102,138)
Conversion of units to common stock, shares																			1,345,231
Issuance of warrants in lawsuit settlement	16,692																			16,692									16,692
Issuance of common stock in connection with employee stock plans, net	48,965											$ 385								48,580									48,965
Issuance of common stock in connection with employee stock plans, net, shares												385,148
Stock and Unit-based compensation	3,895,781																			3,895,781									3,895,781
Balances, end of period at Dec. 31, 2019	$ 24,897,118
Balances, end of period, shares at Dec. 31, 2019	29,835,183											29,835,183
Balances, end of period at Dec. 31, 2019	$ 24,897,118											$ 29,835								$ 107,752,066				$ (83,479,098)			$ (41,295)		$ 24,261,508					$ 635,610

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net loss from operations	$ (45,147,883)	$ (55,765,455)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of warrants and embedded derivative		1,870,923
Stock based compensation	3,895,781	7,599,496
Depreciation and amortization	249,583	66,663
Amortization of marketable securities discount	(530,104)	(497,267)
Cloud computing arrangement implementation costs	(1,114,568)	(107,754)
Noncash lease expense, net	57,780
Noncash portion of litigation settlement	16,692
Other	76,279	12,136
Changes in operating assets and liabilities:
Accounts receivable, net	(228,541)	(164,390)
Inventories	(4,961,770)	(1,621,615)
Prepaid expenses and other assets	859,204	(1,347,410)
Accounts payable	2,797,727	1,858,519
Accrued expense and other current liabilities	(1,036,721)	1,047,059
Deferred rent		(61,254)
Net cash used in operating activities	(45,066,541)	(47,110,349)
Cash flows from investing activities:
Purchase of marketable securities	(37,224,879)	(81,058,590)
Proceeds from maturities of marketable securities	88,266,000	44,509,684
Purchases of property and equipment	(69,675)	(278,921)
Net cash provided by (used in) investing activities	50,971,446	(36,827,827)
Cash flows from financing activities:
Proceeds from note issued	807,347
Repayments of note issued	(695,469)
Sale of common stock, net of related expenses		78,334,457
Proceeds from shares issued in connection with employee stock purchase plan	48,965
Net cash provided by financing activities	160,843	78,334,457
Effect of changes in exchange rates on cash and cash equivalents	(102,241)	(20,191)
Net increase (decrease) in cash and cash equivalents	5,963,507	(5,623,910)
Cash and cash equivalents – beginning of period	7,600,284	13,224,194
Cash and cash equivalents – end of period	13,563,791	7,600,284
Supplemental schedule of noncash financing activity:
Reclass of warrant liability to additional paid in capital		4,110,467
Reclass of deferred financing costs to additional paid in capital		856,985
Stock dividend distribution in connection with IPO		3,629,092
Capitalized cloud computing arrangement costs included in accounts payable and accrued expenses		287,650
Cash paid during the year for:
Income taxes paid	29,542	45,641
Interest paid	$ 3,457
Series A Preferred Units
Supplemental schedule of noncash financing activity:
Equity converted to common stock		53,518,463
Series B Preferred Units
Supplemental schedule of noncash financing activity:
Equity converted to common stock		68,755,544
Common Units
Supplemental schedule of noncash financing activity:
Equity converted to common stock		$ 40,180,619

Business

12 Months Ended

Dec. 31, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Business

Note 1. Business

Company Overview

electroCore, Inc. (“electroCore” or the “Company”) is a commercial stage medical device company, engaged in the commercialization and development of a range of patient administered non-invasive Vagus Nerve Stimulation (“nVNS”) therapies. electroCore was founded in 2005 and its focus currently is on primary headache conditions (migraine and cluster headache).

electroCore, headquartered in New Jersey, has wholly owned subsidiaries that include: electroCore Germany GmbH, and electroCore UK Ltd. The Company’s subsidiary, electroCore Bermuda, Ltd. was dissolved in October 2019. In addition, an affiliate, electroCore (Aust) Pty Limited, is subject to electroCore’s control on a basis other than voting interests and is a variable interest entity (“VIE”), for which electroCore is the primary beneficiary.

In January 2018, the U.S. Food and Drug Administration ("FDA") released the use of gammaCore, the Company's first generation disposable non-invasive vagus nerve stimulator therapy for the treatment of pain associated with migraine headache in adult patients. Previously in April 2017, the FDA released the use of gammaCore for the acute treatment of pain associated with episodic cluster headache in adult patients. Effective August 1, 2018, the Company announced gammaCore Sapphire, a rechargeable and reloadable version of the product for multi-year use, was available in the United States. The Company continues to market the non-reloadable disposable version of its gammaCore products in certain markets and to deploy it for use in clinical studies where a rechargeable version is not necessary.

In November 2018, the FDA provided 501(k) clearance for an expanded label for gammaCore nVNS therapy for adjunctive use for the preventive treatment of cluster headache in adult patients.

In March 2020, the FDA provided 501(k) clearance for an expanded label for gammaCore nVNS therapy for the preventive treatment of migraine headache in adult patients.

Corporate Conversion and Initial Public Offering

Effective June 21, 2018, the Company converted into a Delaware corporation pursuant to a statutory conversion and changed its name to electroCore, Inc. Previously, the Company operated as a Delaware limited liability company under the name Electrocore, LLC. As a result of the corporate conversion, the holders of the different series of units of Electrocore, LLC, or Units, became holders of common stock and options to purchase common stock of electroCore, Inc. Warrants to purchase Units were converted to warrants to purchase common stock of electroCore, Inc. The number of shares of common stock, options to purchase common stock, and warrants to purchase common stock that holders of Units and warrants to purchase Units were entitled to receive in the corporate conversion was determined in accordance with a plan of conversion that was based upon the terms of the Third Amended and Restated Limited Liability Company Agreement, dated November 21, 2017 (the “Operating Agreement”), and varied depending on which class and series of Units a holder owned, and the terms of the applicable warrants. See Note 14 - Corporate Conversion and Equity.

In June 2018, the Company completed its initial public offering ("IPO") and issued 5,980,000 shares of common stock, including the underwriter’s exercise of their right to purchase additional shares, at an initial offering price to the public of $15.00. The Company received net proceeds from the IPO of approximately $77.5 million, after deducting underwriting discounts and commissions and offering costs of approximately $12.2 million.

Significant Accounting Policies

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Significant Accounting Policies

Note 2. Significant Accounting Policies

(a) Basis of Presentation

The accompanying consolidated financial statements were prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”).

(b) Principles of Consolidation

The accompanying consolidated financial statements include the accounts of electroCore and its wholly owned subsidiaries. electroCore (Aust) Pty Limited, a VIE for which electroCore is the primary beneficiary, is also consolidated with the non-controlled equity presented as non-controlling interest. All intercompany balances and transactions have been eliminated in consolidation.

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the useful lives of fixed assets; allowances for doubtful accounts and sales returns; valuation of inventory, property and equipment, warrants and derivative instruments, stock compensation, and contingencies.

(d) Revenue Recognition

The Company accounts for its revenue transactions under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC Topic 606”). In accordance with ASC Topic 606, the Company recognizes revenues when its customers obtain control of its product for an amount that reflects the consideration it expects to receive from its customers in exchange for that product. To determine revenue recognition for contracts that are determined to be in scope of ASC Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Once the contract is determined to be within the scope of ASC Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when such performance obligation is satisfied.

The transaction price is based on the consideration that the Company expects to receive in exchange for its products and includes the fixed per-unit price of the product and variable consideration in the form of trade credits, vouchers, rebates, and co-payment assistance. The per-unit price is based on the Company’s established wholesale acquisition cost less a contractually agreed upon distributor discount with the customer.

Trade credits are discounts that are contingent upon a timely remittance of payment and are estimated based on historical experience. Damaged or defective products are replaced at no charge under the Company’s standard warranty. A cash refund is allowed under specific circumstances for undamaged and non-defective returned products.

Shipping fees are not billed to the customer and are reflected as part of selling, general, and administrative expenses.

(e) Cash and Cash Equivalents

Cash and cash equivalents include all highly liquid investments with a maturity of three months or less when purchased.

(f) Marketable Securities

Marketable securities, all of which are available-for-sale, consist of corporate debt securities, U.S. bonds and U.S. sponsored agencies. Marketable securities are carried at fair value, with unrealized gains and losses reported as accumulated other comprehensive income, except for losses from impairments which are determined to be other-than-temporary. Realized gains and losses and declines in value judged to be other-than-temporary are included in the determination of net loss and are included in interest and other income net. Fair values are based on quoted market prices at the reporting date. Interest and dividends on available-for-sale securities are included in Interest and other income.

(g) Concentration of Credit Risk

Cash, cash equivalents and marketable securities are financial instruments that potentially subject the Company to concentration of credit risk. The Company periodically invests its cash in corporate debt securities, U.S. bonds, and U.S. sponsored agencies and municipal bonds with strong credit ratings. The Company has established guidelines relative to diversification and maturities that are designed to help ensure safety and liquidity. These guidelines are periodically reviewed to take advantage of trends in yields and interest rates.

(h) Accounts Receivable

Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company maintains an allowance for doubtful accounts for estimated losses inherent in its accounts receivable portfolio. Management considers an account receivable to be past due when it is not settled under its stated terms. In establishing the required allowance, management considers historical losses adjusted to take into account current market conditions and customers’ financial condition, the amount of receivables in dispute, and the current receivables aging and current payment patterns. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company does not have any off balance sheet credit exposure related to its customers.

The Company controls its exposure to credit risk through credit analysis and approvals, credit limits, and monitoring procedures. Collateral is generally not required for the Company’s accounts receivables. Management believes the credit risk is limited.

(i) Inventories

Inventory, which consists of raw materials, work-in-process and finished product, is stated at the lower of cost and net realizable value. Inventory is valued on a first-in first-out basis. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.

The Company evaluates inventory with respect to its operating cycle and classifies inventory as current or long-term on its balance sheet. Based upon estimated production needs and current inventory levels, the Company determined the amount of inventory necessary for the next twelve months. Any amounts over this projection are reclassified as Inventories, noncurrent.

In addition, the Company’s product is subject to strict quality control and monitoring which the Company performs throughout the manufacturing process. If certain units of product no longer meet quality specification or become obsolete, the Company records a charge to cost of sales sold to write down such unmarketable inventory to zero.

(j) Property and Equipment

Property and equipment are stated at historical cost. Depreciation is computed by the straight-line method based on the estimated useful lives of the respective assets, as discussed below. Leasehold improvements are amortized over the lesser of the lease terms or the estimated useful lives of the assets. Amounts expended for maintenance and repairs are charged to expense as incurred.

Depreciation and leasehold improvement amortization is computed using the following estimated useful lives:

Machinery and equipment		3–15 years
Leasehold improvements		Lease term
Furniture and fixtures		5–10 years
Computer equipment		5 years

(k) Leases

The Company determines if an arrangement is a lease at inception. For each lease, the lease term is determined at the commencement date and includes renewal options and termination options when it is reasonably certain that the Company will exercise that option. Operating leases with the lease terms greater than one year are included in operating lease right-of-use (“ROU”) assets and current and long-term operating lease liabilities in the Company’s consolidated balance sheets.

Operating lease ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term using an estimated rate of interest the Company would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The operating lease ROU assets are based on the liability adjusted for any prepaid or deferred rent and lease incentives. The incremental borrowing rate was utilized to discount lease payments over the expected term given that the Company’s operating leases do not provide an implicit rate. The Company estimates the incremental borrowing rate to reflect the profile of secured borrowing over the expected term of the leases based on the information available at the later of the date of adoption or the lease commencement date. Rent expense for the operating lease is recognized on a straight-line basis over the lease term.

The new lease accounting guidance permits companies to utilize certain practical expedients in their implementation of the new standard. The Company elected this package of practical expedients and was therefore not required to reassess the following upon adoption: (i) whether an expired or existing contract met the definition of a lease; (ii) the lease classification at January 1, 2019 for existing leases; and (iii) whether leasing costs previously capitalized as initial direct costs would continue to be amortized. This allowed the Company to continue to account for its existing office space leases as operating leases. Upon adoption, the Company did not have an adjustment to the opening balance of retained earnings due to the election of these practical expedients.

(l) Cloud Computing Arrangement

Implementation costs for the Company’s cloud computing arrangement (“CCA”) are capitalized and amortized using the straight-line method over the life of the arrangement. The Company has capitalized implementation costs incurred in implementing its cloud computing arrangements, which is a hosting arrangement that is a service contract per FASB Accounting Standards Update (“ASU”) 2018-15. These costs include payroll costs of employees devoting time to the project and external direct costs for materials and services are capitalized. Software maintenance and training costs are expensed in the period in which they are incurred. The capitalized costs are included as a component of other assets.

(m) Impairment of Long-Lived Assets

Long lived assets, such as property, plant, and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values, and third-party independent appraisals, as considered necessary.

(n) Stock-based Compensation

The Company accounts for stock-based compensation in accordance with the ASC Topic 718, Compensation – Stock Compensation. The Company estimates the fair value of stock option awards using the Black-Scholes option pricing model on the date of the grant. Restricted stock unit awards and restricted stock awards without a market condition are valued based on the closing price of the Company’s common stock on the date of the grant. Compensation expense reflects actual forfeitures and is primarily recognized on a straight-line basis over the requisite service period of the individual grants, which typically equals the vesting period.

In June 2018, the FASB issued ASU 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share Based Payment Accounting (“ASU 2018-07”), which expands the scope of ASC Topic 718, Compensation – Stock Compensation to include share-based payments issued to non-employees for goods or services. Consequently, the Company’s accounting for share-based payments to non-employees and employees was substantially aligned.

(o) Income Taxes

The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred taxes are recognized based on the differences between financial statement and income tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company provides a full valuation allowance on substantially all deferred tax assets. The provision for income taxes represents the current state tax payable for the period. The federal tax provision is immaterial given the Company reports losses in all its taxable jurisdictions and is recording a full valuation allowance on the net deferred tax asset. The Company recognizes the effect of an income tax position only if, based on its merits, the position is more likely than not to be sustained on audit by the taxing authorities. Interest and penalties related to uncertain tax positions are recorded as income tax expense.

(p) Research and Development

Research and development costs are expensed as incurred. These costs include, but are not limited to, costs related to clinical trials, and compensation and related overhead for employees and consultants involved in research and development activities.

(q) Foreign Currency Translation and Transactions

The functional currency of the Company’s international operations has been determined to be the respective local currency. The Company translates functional currency assets and liabilities to their U.S. dollar equivalents at exchange rates in effect at the balance sheet date and translates functional currency income and expense amounts to their U.S. dollar equivalents at average exchange rates for the period. The U.S. dollar affects that arise from changing translation rates are recorded in other comprehensive loss. Foreign currency transaction gains and losses related to assets and liabilities that are denominated in a currency other than the functional currency are reported in the Consolidated Statements of Operations in the period they occur.

(r) Segment Information

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as one operating segment.

(s) Recently Adopted Accounting Pronouncements

In February 2016, the FASB established Topic 842, Leases by issuing ASU No. 2016-02 which requires lessees to recognize leases on the balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842; ASU No 2018-10, Codification Improvements to Topic 842, Leases, and ASU No. 2018-11, Targeted Improvements. The new standard establishes a right-of-use (ROU) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating.

At January 1, 2019, the Company recognized Lease ROU Assets and Lease Liabilities, principally for its office space leases, in which it is the lessee, on the Consolidated Balance Sheets. (See Note 9. Leases)

(t) Recently Accounting Pronouncements Not Yet Adopted

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326); Measurement of Credit Losses on Financial Instruments, ASU 2016-13 changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, the Company will be required to use a new forward looking “expected loss” model that will replace the current “incurred loss” model and generally will result in the earlier recognition for losses. The Company is required to adjust this new guidance effective January 1, 2020. The Company is reviewing the pronouncement of the new standard and currently does not expect a material effect on its consolidated financial statements.

Significant Risks and Uncertainties

12 Months Ended

Dec. 31, 2019

Risks And Uncertainties [Abstract]

Significant Risks and Uncertainties

Note 3. Significant Risks and Uncertainties

The Company is subject to risks common to emerging medical device companies, including uncertainties related to commercialization of products and failing to secure additional funding.

The Company has experienced significant net losses, and it expects to continue to incur losses for the near future as it operates its sales and marketing infrastructure, increases market acceptance of its gammaCore therapy for the acute treatment of episodic cluster headache, or eCH, the prevention of cluster headache, and the preventive and acute treatment of migraine, and fund its research and development activities. The Company has never been profitable and has incurred net losses in each year since its inception.

The Company incurred net losses of $45.1 million and $55.8 million for the years ended December 31, 2019 and 2018, respectively. As of December 31, 2019, its accumulated deficit was $83.5 million.

The Company’s expected cash requirements for 2020 and beyond are based on the commercialization success of its products and its ability to reduce operating expenses. There are significant risks and uncertainties as to its ability to achieve these operating results, including as a result of the potential adverse impact on its business from the COVID-19 pandemic. Due to these risks and uncertainties, the Company may need to reduce its activities significantly more than in its current operating plan and cash flow projections assume in order to fund its operations to the end of 2020. There can be no assurance that the Company will have sufficient cash flow and liquidity to fund its planned activities, which could force it to significantly reduce or curtail our activities and, ultimately, potentially cease operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

Even if the Company is not required to curtail its activities sooner, its ability to execute its operating plan beyond 2020 depends on its ability to increase revenue, reduce operating expenses and obtain additional funding through the sale of equity and or debt securities, a strategic transaction or otherwise. There is no assurance that the Company will generate sufficient funding through its operating results or sale of securities, raising substantial doubt about the Company’s ability to continue as a going concern within one year of the date these financial statements are issued. The accompanying financial statements do not include any adjustment that might result from the outcome of this uncertainty.

Revenue Recognition

12 Months Ended

Dec. 31, 2019

Revenue From Contract With Customer [Abstract]

Revenue Recognition

Note 4. Revenue Recognition

Geographical Market Net Sales

The following table presents net sales disaggregated by geographic area:

	Year ended December 31,
	2019		2018
Geographic Market
United States	$	1,605,814	$	619,772
United Kingdom		665,627		300,091
Germany		102,427		53,784
Other		16,411		19,306
Total Net Sales	$	2,390,279	$	992,953

Performance Obligations

Revenue, net of distribution discounts, vouchers, rebates, returns, and co-payment assistance is solely generated from the sales of the gammaCore products. Revenue is recognized when delivery of the product is completed. The Company deems control to have transferred upon the completion of delivery because that is the point in which (1) it has a present right to payment for the product, (2) it has transferred the physical possession of the product, (3) the customer has legal title to the product, (4) the customer has risks and rewards of ownership and (5) the customer has accepted the product. After the products have been delivered and control has transferred, the Company has no remaining unsatisfied performance obligations.

Revenue is measured based on the consideration that the Company expects to receive in exchange for gammaCore, which represents the transaction price. The transaction price includes the fixed per-unit price of the product and variable consideration in the form of trade credits, vouchers, rebates, and co-payment assistance. The per-unit price is based on the Company’s established wholesale acquisition cost less a contractually agreed upon distributor discount with the customer. Any reserves based on estimated rebates with private payers was determined to be immaterial.

Trade credits are discounts that are contingent upon a timely remittance of payment and are estimated based on historical experience.

From February 2018 to mid-July 2018, the Company had a voucher program under which vouchers were issued to physicians to provide new patients with free therapy (i.e., one gammaCore device) by delivering non-voucher units for free therapy. The transaction price of the non-voucher units redeemed and estimated to be redeemed was recognized as contra-revenue. The cost to produce these units, in addition to any processing fees, are included as promotional expenses in selling, general, and administrative expense. After mid-July 2018, the Company modified its voucher program to provide its distributor with gammaCore and gammaCore Sapphire promotional units at no charge (“voucher units”). The voucher units have a distinct product item number to be used for the voucher program. The costs to produce these voucher units given to patients under the voucher program are recognized in promotional expense.

In October 2018, the Company launched its Partners for Coverage program that allows eligible commercial insurance patients uninterrupted access to gammaCore for up to two months while insurance coverage is being pursued. In February 2019, this program was modified to provide therapy to patients for up to 12 months while insurance coverage is being pursued. In December 2019, the Company terminated this program.

In addition, reimbursement for co-payments made by patients under the co-payment assistance program is considered variable consideration. Beginning in February 2019, eligible patients could receive a reduction of up to $300 from the cost of co-payments for the first month of therapy and a reduction of up to $250 from the cost of each refill for a maximum of 12 months. For the years ended December 31, 2019 and 2018, net sales reflect a reduction for the reduced cost of therapy under the co-payment assistance program. The calculation of the accrual is based on an estimate of claims and the cost per claim that the Company expects to incur associated with inventory that exists in the distribution channel at period end.

Effective March 1, 2020, the amount of monthly co-payment assistance has been reduced to a maximum of $100 per prescription.

Managed care rebates represent our estimated obligations to pharmacy benefit managers. Rebate accruals are recognized in the same period the related revenue is recognized. Gross to net accruals based on estimated rebates were determined to be de minimis.

Contract Balances

The Company generally invoices the customer and recognizes revenue once its performance obligations are satisfied, at which point payment is unconditional. Accordingly, under ASC 606, the Company’s contracts with customers did not give rise to contract assets or liabilities during the year ended December 31, 2019 and 2018.

Agreed upon payment terms with customers are within 120 days of shipment. Accordingly, contracts with customers do not include a significant financing component.

The Company earns a significant amount of its revenue in the U.S. from the Veterans Administration and Department of Defense pursuant to its qualifying contract under the Federal Supply Schedule and open market sales to individual VA facilities and in the U.K. under the National Health Service.

Cash, Cash Equivalents and Marketable Securities

12 Months Ended

Dec. 31, 2019

Investments Debt And Equity Securities [Abstract]

Cash, Cash Equivalents and Marketable Securities

Note 5. Cash, Cash Equivalents and Marketable Securities

The following tables summarizes the Company’s cash, cash equivalents and marketable securities as of December 31, 2019 and 2018.

As of December 31, 2019
	Amortized Cost		Unrealized Gain		Unrealized (Loss)			Fair Value
Cash and cash equivalents	$	13,564,252	$	—	$	(461	)	$	13,563,791

U.S. Treasury Bonds		10,494,539		811		—			10,495,350
Total marketable securities	$	10,494,539	$	811	$	—		$	10,495,350

Total cash, cash equivalents and marketable securities	$	24,058,791	$	811	$	(461	)	$	24,059,141

As of December 31, 2018
	Amortized Cost		Unrealized Gain		Unrealized (Loss)			Fair Value
Cash and cash equivalents	$	7,600,284	$	—	$	—		$	7,600,284

Corporate Debt Securities	$	18,961,145	$	—	$	(25,888	)	$	18,935,257
Commercial Paper		6,970,867		—		(4,927	)		6,965,940
U.S. Treasury Bonds		35,074,005		—		(12,115	)		35,061,890
Total marketable securities	$	61,006,017	$	—	$	(42,930	)	$	60,963,087

Total cash, cash equivalents and marketable securities	$	68,606,301	$	—	$	(42,930	)	$	68,563,371

The Company’s U.S. treasury bonds mature within one year.

Fair Value Measurements

12 Months Ended

Dec. 31, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurements

Note 6. Fair Value Measurements

Financial assets and liabilities carried at fair value are classified and disclosed in one of the following three levels of the fair value hierarchy:

•

Level 1—Quoted prices in active markets for identical assets or liabilities.

•

Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.

•

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

A summary of the assets and liabilities carried at fair value in accordance with the hierarchy defined above is as follows:

			Fair Value Hierarchy
December 31, 2019	Total		(Level 1)		(Level 2)		(Level 3)
Assets
Cash and cash equivalents	$	13,563,791	$	13,563,791	$	—	$	—
Marketable Securities:
U.S. Treasury Bonds		10,495,350		10,495,350		—		—
Total	$	24,059,141	$	24,059,141	$	—	$	—

December 31, 2018
Assets
Cash and cash equivalents	$	7,600,284	$	7,600,284	$	—	$	—
Marketable Securities:
Corporate Debt Securities		18,935,257		18,935,257		—		—
Commercial Paper		6,965,940		6,965,940		—		—
U.S. Treasury Bonds		35,061,890		35,061,890		—		—
Total	$	68,563,371	$	68,563,371	$	—	$	—

The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers within the hierarchy during the years ended December 31, 2019 and 2018. The carrying amount of the Company’s receivables and payables approximate their fair value due to their maturity.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Inventory

12 Months Ended

Dec. 31, 2019

Inventory Disclosure [Abstract]

Inventory

Note 7. Inventory

As of December 31, 2019 and 2018, inventories consisted of the following:

	December 31,
	2019		2018
Raw materials	$	1,065,345	$	821,704
Work in process		5,314,763		951,695
Finished Goods		531,064		176,003
Total Inventory		6,911,172		1,949,402
Less: noncurrent inventory		6,020,180		—
Total current inventory	$	890,992	$	1,949,402

As of December 31, 2019, the Company reserved $287,544 for obsolete inventory. As of December 31, 2018, the Company determined that raw materials of $147,450 became obsolete due to the development of new product technology. The 2019 charge was recorded in cost of goods sold, and the 2018 charge was recorded in selling, general, and administrative expense.

Noncurrent inventory is comprised of approximately $1 million of raw materials and $5 million of work in process.

Property and Equipment, Net

12 Months Ended

Dec. 31, 2019

Property Plant And Equipment [Abstract]

Property and Equipment, Net

Note 8. Property and Equipment, Net

Property and equipment, net, as of December 31, 2019 and 2018 consisted of the following:

	December 31.
	2019			2018
Machinery and equipment	$	393,154		$	424,146
Furniture and fixture		310,820			286,268
Computer equipment and software		20,783			20,783
Leasehold improvements		8,880			—
Property and equipment - gross		733,637			731,197
Less: accumulated depreciation		(388,401	)		(350,293	)
Property and equipment, net	$	345,236		$	380,904

During the year ended December 31, 2019, $70,639 of fully depreciated laboratory and production equipment, and office furniture were written off. During the year ended December 31, 2018, $295,384 of fully depreciated assets in the Company’s Bermuda subsidiary and Australian affiliate were written off. Depreciation expense for the years ended December 31, 2019 and 2018 was $108,546 and $66,663, respectively.

Leases

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Leases

Note 9. Leases

The Company implemented FASB ASU 2016-02, Leases (Topic 842), which required lessees to recognize most leases on its balance sheet effective January 1, 2019. The Company recognized $3.9 million of right of use assets for leases for office, manufacturing and warehouse space and office equipment. The Company also recognized $4.2 million for lease liabilities. The Company has elected not to recognize right of use assets and lease liabilities for short term leases, i.e., leases with a noncancelable period of 12 months or less.

The Company’s leases have remaining lease terms of approximately three to five years, some of which include options to extend the leases for up to an additional five years. For the leases for the office space in Basking Ridge New Jersey and the manufacturing and warehouse space in Rockaway New Jersey, the Company recognized the options to renew the leases as part of the right of use asset and the lease liability as the Company deemed that the renewal options were reasonably certain to be exercised. However, due to the Company’s decision to implement a comprehensive redeployment and cost reduction plan implemented in June 2019, the Company determined the renewal option for the office space at the Basking Ridge location is no longer reasonably certain to be exercised. The Company remeasured the Basking Ridge right of use asset and the lease liability beginning June 1, 2019 utilizing the newly expected lease term.

The incremental borrowing rate used to determine the net present value of the leases at inception was 9.75%. This is the incremental borrowing rate that represents the rate of interest that the Company would expect to pay to borrow an amount equal to the lease payments under similar terms. As the Company does not borrow on a collateralized basis, the non-collateralized borrowing rate is used as an input in deriving the incremental borrowing rate. Following the comprehensive redeployment and cost reduction plan announcement and as required in the lease remeasurement process under Topic 842, the incremental borrowing rate was reassessed and increased to 13.75% at the time of remeasurement. The remeasurement updated the net present value of all operating leases from inception using the new discount rate at June 1, 2019.

For the years ended December 31, 2019 and 2018, the Company recognized lease expense of $787,952 and $496,055, respectively. This expense does not include non-lease components associated with the lease agreements as the Company elected not to include such charges as part of the lease expense.

The tables below provide the details of the right of use assets and lease liabilities:

Supplemental Balance Sheet Information for Operating Leases:

	December 31, 2019
Operating leases:
Operating lease right of use assets	$	1,430,641
Operating lease liabilities:
Current portion of operating lease liabilities		486,445
Noncurrent operating lease liabilities		1,419,880
Total operating lease liabilities	$	1,906,325
Weighted average remaining lease term (in years)		5.9
Weighted average discount rate		13.75	%

Supplemental Statement of Cash Flows Information for Operating Leases:

	For the year ended December 31, 2019
Noncash lease expense		315,458
Change in operating lease liabilities		(257,678	)

Future minimum lease payments under non-cancellable operating leases as of December 31, 2019:

Financial year
2020	$	712,076
2021		690,358
2022		337,254
2023		142,892
2024		146,044
2025 and thereafter		676,260
Total future minimum lease payments		2,704,884
Less: Amounts representing interest		(798,559	)
Total	$	1,906,325

Total lease expense, in accordance with the superseded lease standard was $496,055 for 2018. Future minimum lease payments under non-cancellable operating leases as of December 31, 2018 were as follows:

Financial year
2019	$	576,743
2020		714,616
2021		692,893
2022		737,324
2023 and thereafter		3,696,796
Total	$	6,418,372

Cloud Computing Arrangement

12 Months Ended

Dec. 31, 2019

Cloud Computing Arrangement [Abstract]

Cloud Computing Arrangement

Note 10. Cloud Computing Arrangement

In 2018, the Company entered into a contract to obtain a cloud computing arrangement (“CCA”). In accordance with ASU 2018-15, the implementation costs incurred in the CCA were deferred and recognized as other assets and are being amortized to expense over the noncancelable term of the arrangement. The Company capitalized $826,918 in CCA costs for the year ended December 31, 2019 and $395,404 in 2018. The implementation of this CCA was completed on June 30, 2019. Beginning July 1, 2019, the Company went live with the cloud computing Enterprise Resource Planning system and all future related costs are expensed as incurred. In July 2019, the Company began amortizing the related deferred costs over the remaining period of the noncancelable arrangement. Amortization costs for the year ended December 31, 2019 were $141,037.

Accrued Expenses

12 Months Ended

Dec. 31, 2019

Payables And Accruals [Abstract]

Accrued Expenses

Note 11. Accrued Expenses

Accrued expenses as of December 31, 2019 and 2018 consisted of the following:

	December 31,
	2019		2018
Accrued professional fees	$	1,255,494	$	1,273,249
Accrued bonuses		804,082		2,152,264
Other accrued expenses		1,277,803		948,588
	$	3,337,379	$	4,374,101

Note Payable

12 Months Ended

Dec. 31, 2019

Notes Payable [Abstract]

Note Payable

Note 12. Note Payable

On July 1, 2019, the Company entered into a Commercial Insurance Premium Finance and Security Agreement (“the Agreement”). The Agreement provides for a single borrowing by the Company of $807,347, with a seven-month term, and an annual interest rate of 2.99%. The proceeds from this transaction were used to partially fund the premiums due under some of the Company’s insurance policies. The amounts payable are secured by the Company’s rights under such policies. At December 31, 2019, the remaining balance is $111,878 and during the year ended December 31, 2019, the Company recognized $3,457 in interest expense. The balance was fully paid as of January 2020.

Net Loss Per Share

12 Months Ended

Dec. 31, 2019

Earnings Per Share [Abstract]

Net Loss Per Share

Note 13. Net Loss Per Share

Basic net loss per share is computed by dividing net loss available to electroCore, Inc. by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per share is computed by dividing net loss available to electroCore, Inc. by the weighted-average number of shares of common stock outstanding adjusted to give effect to potentially dilutive securities. Restricted stock awards and units, and stock options have not been included in the diluted loss per share calculation as their inclusion would have had an anti-dilutive effect.

As described in Note 14, Corporate Conversion and Equity, on June 21, 2018, electroCore, Inc. completed a Corporate Conversion as well as its initial public offering to, among other things, provide for a single class of common stock of electroCore, Inc., in exchange for the previous convertible preferred units and common units of the Company. This conversion changed the relative ownership of electroCore, Inc. such that retroactive application of the conversion to periods prior to the IPO for the purposes of calculating loss per share would not be meaningful. Net loss attributable to electroCore, Inc. subsidiaries and affiliate for the year ended December 31, 2018 of $1.19 per share includes the loss attributable to the period June 21, 2018 to December 31, 2018 and is based on the number of days in which the shares were outstanding during the period June 21, 2018 to December 31, 2018.

The potential common stock equivalents that have been excluded from the computation of diluted loss per share consist of the following:

	December 31,
	2019		2018
Outstanding stock options		3,131,266		2,228,904
Nonvested restricted stock and unit awards		1,368,998		265,569
Stock purchase warrants		62,181		—

Corporate Conversion and Equity

12 Months Ended

Dec. 31, 2019

Equity [Abstract]

Corporate Conversion and Equity

Note 14. Corporate Conversion and Equity

On June 21, 2018, the Company completed the Corporate Conversion. Pursuant to the certificate of incorporation effected in connection with the Corporate Conversion, the Company’s authorized capital stock consists of 500 million shares of common stock, par value $0.001 per share and 10 million shares of preferred stock, par value $0.001 per share. As a result of this conversion and related initial public offering, 29,450,035 shares of common stock and zero shares of preferred stock were issued. On June 22, 2018, the common stock began trading on the Nasdaq Global Market under the symbol “ECOR”. Prior to the Corporate Conversion of the Company, the Operating Agreement permitted the issuance of four classes of Units - Series A Preferred Units, Series B Preferred Units, Series B-1 Preferred Units and Common Units. Except as otherwise provided in the Operating Agreement, each member was entitled to one vote for each Unit held and the Units of all classes and series voted together as a single class on all matters (on an as converted to common unit basis).

Upon the Corporate Conversion, all Units were converted into an aggregate of 23,470,035 shares of common stock and options to purchase 2,141,748 shares of common stock as follows:

•

holders of Common Units, other than Common Units that were originally issued as “profits interests” (as such term is used for purposes of the Internal Revenue Code) (“Profits Interests”) received an aggregate of 12,099,280 shares of common stock;

•

holders of Series A Preferred Units received an aggregate of 4,181,856 shares of common stock, which included 241,939 shares of common stock as payment in full of the approximately $3.6 million accrued and unpaid preferred return that was payable in respect of the Series A Preferred Units;

•

holders of Series B Preferred Units received an aggregate of 5,843,668 shares of common stock;

•

holders of Profits Interests received an aggregate of 1,345,231 shares of common stock; and

•

holders of Profits Interests who were employees or consultants at the time of the corporate conversion received options to purchase an aggregate of 2,141,748 shares of common stock, with an exercise price of $15.00 which was equal to the initial public offering price.

Additionally, upon the conversion, the accumulated deficit of Electrocore LLC, subsidiaries and affiliates was reclassed to additional paid in capital in accordance with SEC SAB Topic 4B.

Series A Preferred Units

The Series A Preferred Units were entitled to a preference on distributions, ahead of the Common Units but behind Series B Preferred Units, in the amount of $54,923,430 plus the Series A Preferred Return (as described below), as of June 20, 2018.

The Series A Preferred Units were entitled to a return in an annual non-compounded amount with respect to each outstanding Series A Preferred Unit equal to the product of the Series A Preferred Return Percentage and the Series A Unreturned Capital Value for each Unit, which accrued to the extent not paid. The Series A Preferred Return Percentage was 4% and could be reduced to 2% if certain requirements were met as outlined in the amended and restated Operating Agreement. Upon an IPO, the payment of the Series A Preferred Return was at the sole discretion of the Board of Managers. As of June 20, 2018, the Series A Preferred Return payable, following the 2017 amendments to the Operating Agreement, upon a public offering of the Company’s common stock was fixed at $3,629,092. This amount was paid with the issuance of 241,939 shares of common stock upon the IPO.

The Series A Preferred Units were converted into common stock mandatorily immediately prior to the initial public offering as outlined in the amended and restated Operating Agreement, and then subject to a 1:18 stock conversion.

As of December 31, 2018, there were no outstanding warrants to purchase Series A Preferred Units, except for warrants to purchase in the aggregate 221,766 Series A Preferred Units issued in connection with the December 2015 term loan (which was repaid and/or converted into equity in 2016) and as compensation to one of the financial advisors. In connection with the IPO, these outstanding Series A warrants by their terms converted into warrants to purchase in the aggregate 12,321 shares of common stock at an exercise price of $15.30 per share.

Series B Preferred Units

In 2017, the Company entered into a Series B Preferred Unit Purchase Agreement with multiple investors, including Core Ventures II, LLC and Merck Global Health Innovation Fund. Under the terms of the Purchase Agreement, as amended, through December 31, 2017, the Company received cash proceeds of $46,911,300 and converted $26,718,910 of outstanding promissory notes (the “Bridge Notes”) and related accrued and unpaid interest for an aggregate amount of $73,630,210 (inclusive of amounts mentioned in Note 17 related to conversion of Bridge Notes and related accrued and unpaid interest) through the sale of Series B Preferred Units at an initial closing and several additional closings.

Each Series B Preferred Unit was converted into one Common Unit mandatorily upon the occurrence of the Corporate Conversion as outlined in the amended and restated Operating Agreement, and then subject to an 1:18 stock conversion pursuant to the terms of the plan of conversion for the Corporate Conversion. In connection with all Series B Preferred Unit closings, the Company issued warrants for the purchase of 35,452,084 Common Units at an exercise price of $1.25 per Unit, which expired unexercised upon the closing of the IPO. The Company also issued warrants to advisors for the purchase of 2,724,549 common units at an exercise price of $0.70 per Unit. The Company also issued 72,000 warrants to purchase common units with an exercise price of $1.25 per Unit, which expired upon the closing of the IPO. The fair value of these warrants to purchase common units were recorded within additional-paid-in-capital. In connection with the Corporate Conversion, the 2,724,549 warrants issued to advisors were converted to warrants to purchase 151,364 shares of common stock at an exercise price of $12.60 per share of common stock.

As of June 21, 2018, the Series B warrants that were issued to purchasers of the Bridge Notes were converted to (i) warrants to purchase 429,948 shares of common stock at an exercise price of $12.60 per share (see Note 17) and (ii) the Series B Preferred warrants that were issued to financial advisors were converted into warrants to purchase 101,119 shares of common stock at an exercise price of $12.60 per share.

Variable Interest Entity

12 Months Ended

Dec. 31, 2019

Variable Interest Entity [Abstract]

Variable Interest Entity

Note 15. Variable Interest Entity

As discussed in Note 1, electroCore is the primary beneficiary of electroCore (Aust) Pty Limited. electroCore has contributed certain intellectual property rights, all rights to distribute, market and sell specified products in Australia and New Zealand, and other rights outlined in the shareholders’ deed of electroCore (Aust) Pty Limited in return for 50% of the shares of such entity. In addition, electroCore can also appoint two of the four directors and can exercise significant influence. This along with the fact that electroCore is electroCore (Aust) Pty Limited’s only supplier causes electroCore, for accounting purposes, to be the primary beneficiary of electroCore (Aust) Pty Limited. The activities related to electroCore (Aust) Pty Limited are not material to the consolidated financial statements.

Income Taxes

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Income Taxes

Note 16. Income Taxes

The provision for income taxes for the years ended December 31, 2019 and 2018 related to foreign taxes and state minimum taxes. The Company has incurred operating losses since inception in the US. Prior to the Corporate Conversion on June 21, 2018, the Company was a limited liability company in the United States, which is treated as a flow-through entity for Federal and state income tax purposes. Accordingly, the Company was not subject to U.S. income taxes until its conversion.

The Company has evaluated the available evidence supporting the realization of its deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that its net deferred tax assets will not be realized in the United States and certain foreign jurisdictions. Due to uncertainties surrounding the realization of the deferred tax assets, the Company maintains a full valuation allowance against all of its net deferred tax assets. When the Company determines that it will be able to realize some portion or all of its deferred tax assets, an adjustment to its valuation allowance on its deferred tax assets would have the effect of increasing net income in the period such determination is made.

A reconciliation of the income tax provision computed at statutory rates to the reported income tax provision for the years ended December 31, 2019 and 2018 is as follows:

	Year ended December 31,
	2019	2018
Statutory rate	21.0%	21.0%
State tax expected (recovery), net of federal benefit	6.7%	2.6%
Nondeductible expenses	(0.13)%	(2.9)%
Loss incurred as pass-through	—%	(7.9)%
Change in valuation allowance for deferred tax assets	(27.6)%	(12.8)%
Provision for income taxes	(0.04)%	—%

The net change in the valuation allowance was an increase of $12.4 million.

The significant components of the Company’s deferred income tax assets and liabilities after applying enacted corporate tax rates are as follows:

	Year ended December 31,
	2019			2018
Deferred tax assets
Net operating loss carryforwards	$	18,883,686		$	7,578,570
Accrued expenses		796,849			735,910
Intangibles		355,288			290,098
Inventory		78,206			66,935
Deferred rent		—			65,574
Charitable contributions		19,028			10,602
R&D credit		394,981			—
Lease liabilities		518,480			—
Stock compensation		750,449			—
Deferred tax assets		21,796,967			8,747,689
Less valuation allowance		(21,171,967	)		(8,722,389	)
Total deferred tax assets		625,000			25,300
Fixed assets		(15,222	)		(25,300	)
Prepaid expenses		(220,673	)		—
Right of use asset		(389,105	)		—
Total deferred tax liabilities		(625,000	)		(25,300	)
Deferred tax assets, net	$	—		$	—

As of December 31, 2019 and 2018, the Company had accumulated non-capital losses totaling $3.5 and $3.7 million, respectively, in Germany which can be carried forward indefinitely, and net operating losses of $65.7 and $24.6 million respectively, in the U.S. (federal and state), which may be available to carry forward and offset future years’ taxable income. U.S. federal losses can be carried forward indefinitely, and state losses expire in various amounts beginning in 2026.

However, the NOL carryforwards may be, or become subject to, an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, as well as similar state tax provisions. This could limit the amount of NOLs that the Company can utilize annually to offset future taxable income or tax liabilities. The amount of the annual limitation, if any, will be determined based on the value of the Company immediately prior to an ownership change. Subsequent ownership changes may further affect the limitation in future years. If and when the Company utilizes the NOL carryforwards in a future period, it will perform an analysis to determine the effect, if any, of these loss limitation rules on the NOL carryforward balances.

Domestic and foreign components of loss before provision for income taxes is as follows:

	December 31, 2019			December 31, 2018
Domestic	$	(43,661,897	)	$	(55,268,310	)
Foreign		(1,468,287	)		(494,714	)
Total	$	(45,130,184	)	$	(55,763,024	)

The income tax provision from continuing operations contains the following components:

	December 31, 2019		December 31, 2018
Federal	$	—	$	—
State	$	7,712	$	2,431
Foreign	$	9,987	$	—
Total current		17,699		2,431

Total deferred		—		—
Total income tax expense/(benefit)	$	17,699	$	2,431

Uncertain Tax Positions

The Company has adopted certain provisions of ASC 740, “Income Taxes”, which prescribes a recognition threshold and measurement attribute for the recognition and measurement of tax positions taken or expected to be taken in income tax returns. The provisions also provide guidance on the de-recognition of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities, and accounting for interest and penalties associated with tax positions.

The Company files income tax returns in the U.S. federal jurisdiction, and in various state and foreign jurisdictions. The Company’s tax returns are subject to tax examinations by U.S. federal and state tax authorities, or examinations by foreign tax authorities until the expiration of the respective statutes of limitation. The Company currently has no tax years under examination.

As of December 31, 2019, the Company does not have an accrual relating to uncertain tax positions. Interest and penalties, if any, as they relate to income taxes assessed, are included in the income tax provision. It is not anticipated that unrecognized tax benefits would significantly increase or decrease within 12 months of the reporting date.

Warrant Liability

12 Months Ended

Dec. 31, 2019

Debt Disclosure [Abstract]

Warrant Liability

Note 17. Warrant Liability

During the period ended June 30, 2017, the Company issued bridge notes together with associated warrants (“Bridge Note Warrants”). Since the Bridge Note Warrants entitled the holders to purchase securities in the qualified equity round at the purchase price payable for the related equity securities, the exercise price of the warrants was undetermined at the time of their issuance. Also, because the terms of redemption of the Series B Preferred Units were unknown at the time of their issuance as well as the deemed liquidation terms, the warrant liability was recorded at fair value and marked to market. The valuation of the warrant liability was determined using Level 3 inputs. In connection with the bridge note closings, at the time of the qualified equity round, the Company issued 7,739,092 Bridge Note Warrants all of which were outstanding as of March 31, 2018. At the time of the Corporate Conversion, these warrants were converted to warrants to purchase 429,948 shares of common stock at an exercise price of $12.60 and were reclassified to equity upon the determination that they no longer met the criteria to be classified as liabilities.

Stock Compensation and Unit-Based Compensation

12 Months Ended

Dec. 31, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock Compensation and Unit-Based Compensation

Note 18. Stock Compensation and Unit-Based Compensation

The issuance of common stock and options to purchase common stock to prior holders of Profits Interests in connection with the Corporate Conversion was accounted for as a type-1 modification of the old awards. Under the previous LLC structure, in connection with employment and service provider agreements, the Company granted Units that constitute profits interests for income tax purposes to grantees pursuant to Unit Forfeiture Agreements, subject to certain restrictions defined in each such agreement. The Company maintained a Unit award account for each of the grantees. Generally, the Units vested 25% on the one-year anniversary of the employment start date or agreement date and the balance ratably per quarter thereafter over an additional three-year period. After the restrictions lapsed, the grantees became fully vested in such Units. In 2018, the Company granted 19,447,218 Units to its employees, of which 110,354 were forfeited immediately prior to the Corporate Conversion.

In connection with the Corporate Conversion, 62,765,605 Units (outstanding immediately prior to the IPO) were converted, in the aggregate, into (i) 1,345,231 shares of common stock, and (ii) with respect to Units held by current employees and consultants at the time of the conversion, options to purchase 2,141,748 shares of electroCore, Inc. common stock at an exercise price of $15.00 per share.

The number of shares of common stock and the number of options issued for the outstanding units were determined based upon the appreciation in value of the Company after the date of Unit grant through the completion of the IPO.

The number of shares of common stock issued for each Unit (the "Conversion Shares") was equal to (x) the percentage of the capital account balance associated with such Unit as it related to the total value of the Company at the IPO pre-money valuation, divided by (y) the percentage interest in the Company represented by such Unit based on the total outstanding Units in the Company immediately prior to the IPO, multiplied by (z) the total number of Units represented by the applicable Profits Interest. Of the shares of common stock issued for the Units, 1,157,139 vested immediately, 188,092 vested January 1, 2019, and the balance vesting over the next succeeding 10 calendar quarters. The Company accounts for the 1,345,231 shares of common stock as restricted stock awards as reflected in the table below. As of December 31, 2018, the total number of restricted shares outstanding was 185,571 as 2,521 share awards were forfeited and no further share awards were granted in 2018.

The number of options issued in respect of each Unit was equal to (i) the total number of Units represented by such Profits Interest prior to the corporate conversion minus (ii) the Conversion Shares issued in respect of such Profits Interest. Of the options issued for the Units, 228,954 vested 100% on January 1, 2019, 1,912,797 vested 25% on January 1, 2019, and the balance vesting over the next succeeding 14 calendar quarters. The options have an exercise price of $15.00 per share.

Stock compensation expense for the Profits Interests not recognized prior to the Corporate Conversion was $2.8 million. This expense was allocated to the common stock and options to purchase common stock awards based on their relative fair value on the date of the IPO. For the common stock awards that vested at the time of issuance, the Company recognized $1.2 million immediately. At the time of issuance of stock compensation expense for the common stock awards and the options to purchase common stock that did not vest immediately totaled, $0.2 million and $1.4 million, respectively, and is being amortized over the respective vesting periods.

The incremental stock compensation expensed due to the modification was $7.8 million. This expense was allocated to the common stock and the options to purchase common stock based on their fair value on the date of the awards. For the common stock that vested at the time of issuance, the Company recognized $3.8 million. For the common stock awards and the options to purchase common stock that did not vest immediately, the Company will recognize $0.4 million and $3.6 million, respectively, over the respective vesting periods.

On June 21, 2018, the Company adopted the 2018 Omnibus Equity Incentive Plan (“Plan”). This plan reserved 6.2 million shares with an increase to be added annually beginning in 2019 through 2028 up to 4% of the total number of shares of common stock issued and outstanding on a fully diluted basis as of the end of the immediately preceding fiscal year, providing that the aggregate number of additional shares shall not exceed a total of 45 million shares, and a maximum of 40 million shares pursuant to the exercise of stock options. Effective January 1, 2019, the amount of shares reserved under the Plan was increased to approximately 6.9 million. The Company’s policy is to issue new shares of its common stock upon the exercise of stock options, new grants of restricted stock awards, and settlement of restricted stock units. Stock options issued under the plan have a contractual life of 10 years and are generally forfeited upon separation from the Company. The options issued in conjunction with the Corporate Conversion were issued under this Plan. At December 31, 2019 there were approximately 2,120,000 shares available to be awarded under the Plan.

The following table presents a summary of stock options granted:

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding, December 31, 2018		2,228,904		$	14.89		9.5	*
Granted		2,146,699			4.68
Exercised		—			—
Cancelled		(1,244,337	)		13.34
Outstanding, December 31, 2019		3,131,266		$	8.53		8.9	*
Exercisable, December 31, 2019		1,348,994		$	11.99		8.6	*

* de minimis

The intrinsic value is calculated as the difference between the fair market value at December 31, 2019 and the exercise price per share of the stock options. The fair market value per share of common stock as of December 31, 2019 was $1.59. In general, option awards granted to employees and consultants vest over four years.

The following table provides additional information about stock options that are outstanding and exercisable at December 31, 2019:

Exercise Price	Options Outstanding		Weighted Average Remaining Contractual Life (Years)		Options Exercisable
$1.40 - $2.50		1,019,495		9.7		95,635
$2.51 - $7.52		647,629		9.2		324,900
$7.53 - $15.00		1,464,142		8.6		928,459

The following table presents a summary of restricted stock awards granted:

	Number of Shares			Weighted Average Grant Date Fair Value
Nonvested, December 31, 2018		185,571		$	15.00
Granted		204,088			6.88
Vested		(139,473	)		14.25
Cancelled		(122,681	)		9.27
Nonvested, December 31, 2019		127,505		$	8.09

In general, restricted stock awards granted to employees and consultants in 2019 vest over 4 years.

The following table presents a summary of restricted and deferred stock units (“Stock Units”) granted:

	Number of Shares			Weighted Average Grant Date Fair Value
Nonvested, December 31, 2018		79,998		$	15.00
Granted		1,566,205			2.47
Vested		(274,939	)		4.62
Cancelled		(129,771	)		1.90
Nonvested, December 31, 2019		1,241,493		$	2.86

In general, Stock Units awarded to employees and consultants vest over two years.

Immediately following the Company’s annual meeting of stockholders, the Company generally grants each non-employee director an equity award that vests over a 12-month period. Upon a non-employee director’s initial appointment or election to the board of directors, the Company grants such non-employee director an equity award subject to vesting as determined by the board of directors.

For the years ended December 31, 2019 and 2018, stock compensation expense reported as a component of selling, general and administrative expense was $2.7 million and $4.6 million, respectively. For the same period, stock compensation expense reported as a component of research and development expense was $1.1 million and $2.8 million, respectively. For the years ended December 31, 2019 and 2018, stock compensation expense reported as a component of cost of goods sold was $0.1 million and $0.2 million respectively. Total unrecognized compensation cost related to equity awards as of December 31, 2019 was $7.9 million and is expected to be recognized over the next 3 years.

Valuation Information for Stock-Based Compensation

The fair value of each stock option award granted was estimated on the date of grant using the Black-Scholes model. Expected volatility was based on historical volatility of the Company’s common stock. The risk-free interest rate was based on the average U.S. Treasury rate that most closely resembles the expected life of the related award. The expected term of the award was calculated using the simplified method. No dividend was assumed as the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future.

The weighted average assumptions used in the Black-Scholes option pricing model in valuing stock options granted in the periods presented were:

	2019		2018
Fair value at grant date	$	3.39	$	2.50
Expected volatility	95.9%		70.9%
Risk-free interest rate	2.1%		2.7%
Expected holding period, in years		5.9		5.9
Dividend yield		—		—

The fair value of restricted stock awards and restricted stock units is the market close price of the Company’s common stock on the trading day immediately preceding the date of grant.

Employee Stock Purchase Plan

Effective January 1, 2019, the Company adopted the 2019 Employee Stock Purchase Plan. The plan, which was terminated effective January 1, 2020, provided eligible employee of the Company with an opportunity to purchase common stock of the Company through accumulated payroll deductions. The maximum number of shares reserved for delivery under the plan was 300,000 shares, plus an annual increase not to exceed an aggregate of 4,500,000 shares over the life of the plan.

The weighted average assumptions used in the Black-Scholes valuation of the fair value of the discount for the year ended December 31, 2019 were:

	2019
Fair value at grant date	$	0.75
Expected volatility	169%
Risk-free interest rate	2.3%
Expected holding period	6 months
Dividend yield		—

Employee Benefit Plan

12 Months Ended

Dec. 31, 2019

Compensation And Retirement Disclosure [Abstract]

Employee Benefit Plan

Note 19. Employee Benefit Plan

The Company has a defined contribution 401(k) profit sharing plan which covers all employees. Employees are eligible upon date of hire. Employee contributions are voluntary and are based on specific percentages of compensation, which may not exceed maximum amounts established by Internal Revenue Code. Employer contributions are discretionary. There were no employer contributions for the years ended December 31, 2019 and 2018.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2019

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 20. Commitments and Contingencies

Stockholders Litigation

On July 8, 2019 and August 1, 2019, purported stockholders of the Company served putative class action lawsuits in the Superior Court of New Jersey for Somerset County, captioned Paul Kuehl vs. electroCore, Inc., et al., Docket No. SOM-L 000876-19 and Shirley Stone vs. electroCore, Inc., et al., Docket No. SOM-L 001007-19, respectively. In addition to the Company, the defendants include present and past directors and officers, Evercore Group L.L.C., Cantor Fitzgerald & Co., JMP Securities LLC and BTIG, LLC, the underwriters for its IPO; and two of the Company’s stockholders. On August 15, 2019, the Superior Court entered an order consolidating the Kuehl and Stone actions, which are proceeding under Docket No. SOM-L 000876-19. Each plaintiff was appointed a co-lead plaintiff. The plaintiffs filed a consolidated amended complaint, which sought certification of a class of stockholders who purchased common stock in the IPO or whose purchases are traceable to that offering. The consolidated amended complaint alleged that the defendants violated Sections 11, 12(a)(2) and 15 of the Securities Act with respect to the registration statement and related prospectus for the IPO. The complaint sought unspecified compensatory damages, interest, costs and attorneys’ fees. On October 31, 2019, the Company filed a motion to dismiss the complaint or in the alternative to stay the action in favor of the pending federal action (discussed below). On February 21, 2020 the court granted the defendants’ motion to dismiss the consolidated amended complaint with prejudice. On March 2, 2020 the court entered an amended order dismissing the consolidated amended complaint with prejudice. On March 27, 2020, the plaintiffs filed a notice of appeal with the N.J. Superior Court – Appellate Division.

On September 26, 2019 and October 31, 2019, purported stockholders of the Company served putative class action lawsuits in the United States District Court for the District of New Jersey captioned Allyn Turnofsky vs. electroCore, Inc., et al., Case 3:19-cv-18400, and Priewe vs. electroCore, Inc., et al., Case 1:19-cv-19653, respectively. In addition to the Company, the defendants include present and past directors and officers, and Evercore Group L.L.C., Cantor Fitzgerald & Co., JMP Securities LLC and BTIG, LLC, the underwriters for the IPO. The plaintiffs each seek to represent a class of stockholders who (i) purchased the Company’s common stock in the IPO or whose purchases are traceable to the IPO, or (ii) who purchased common stock between the IPO and September 25, 2019. The complaints each allege that the defendants violated Sections 11 and 15 of the Securities Act and Sections 10(b) and 20(a) of the Exchange Act, with respect to (i) the registration statement and related prospectus for the IPO, and (ii) certain post-IPO disclosures filed with the SEC. The complaints seek unspecified compensatory damages, interest, costs and attorneys’ fees.

In the Turnofsky case, several plaintiffs and their counsel are engaged in motion practice to select a lead plaintiff and lead plaintiff’s counsel. Briefing is complete on the motions, but the court has not yet ruled. On February 19, 2020, the Priewe case was voluntarily dismissed.

The Company intends to continue to vigorously defend itself in these matters. However, in light of, among other things, the preliminary stage of these litigation matters, the Company is unable to determine the reasonable probability of loss or a range of potential loss. Accordingly, the Company has not established an accrual for potential losses, if any, that could result from any unfavorable outcome, and there can be no assurance that these litigation matters will not result in substantial defense costs and/or judgments or settlements that could adversely affect the Company’s financial condition.

The Company expenses associated legal fees in the period they are incurred.

Settlement Agreement

In January 2019, the Company settled a dispute with one of its former advisors, Madison Global Partners, who had filed a complaint against us in the Supreme Court of the State of New York, County of New York (Index No. 652329/2018) as previously reported. As part of that settlement, the Company paid Madison Global $325,000 and issued to Madison Global and its representatives warrants to purchase in the aggregate 62,181 shares of Company common stock at prices ranging from $5.68 per share to $12.60 per share. Substantially all such amounts were accrued in prior accounting periods. The warrants issued are shown in the following table:

# Warrants		Exercise Price		Expiration Date
	8,576	$	8.86	April 1, 2021
	22,253	$	5.68	March 30, 2022
	17,066	$	12.60	June 30, 2022
	14,286	$	12.60	August 31, 2022

Claim from Lifehealthcare Pty Ltd.

The Company was party to a joint venture arrangement (“JV Arrangement”) in Australia with Lifehealthcare Pty Ltd (“LHP”). In 2017, the parties agreed to terminate the JV Arrangement. In March 2019, the Company received a letter from LHP alleging certain breaches by the Company under the JV Arrangement, primarily arising out of the Company’s alleged failure to notify LHP of the Company’s IPO. The Company strongly disputes these allegations and notified LHP in writing in April 2019 of its position on this matter and its intent to vigorously defend itself against these claims. The Company has received no further communications from LHP since that time. Although no assurance can be given that LHP will not pursue this matter further, the financial impact, if any, in connection with any potential resolution of this matter is not expected to be material.

Purchase Commitments

The Company enters into contracts in the normal course of business with contract research organizations for its clinical trials, contract manufacturing organizations for the manufacture and supply of its clinical and commercial product needs and other vendors for other research and development and commercial activities, as well as services and products for operating purposes. The Company’s agreements generally provide for termination with notice. Such agreements that are cancelable contracts are not included as purchase commitments. The Company has included as purchase obligations its commitments under agreements to the extent they are quantifiable and are not cancelable. The Company has purchase obligations of approximately $1.7 million as of December 31, 2019.

Restructuring Charges and Other Severance Related Charges

12 Months Ended

Dec. 31, 2019

Restructuring And Related Activities [Abstract]

Restructuring Charges and Other Severance Related Charges

Note 21. Restructuring Charges and Other Severance Related Charges

Restructuring charges

On May 29, 2019, the Company announced significant adjustments to the deployment of personnel and resources across the organization. The effort was intended to focus the Company on currently available and near-term revenue opportunities and on clinical programs specifically designed to expand the gammaCore product labeling. To achieve this goal, the Company reduced the size of its organizational structure, including its field sales force and clinical operations.

The costs associated with this initiative primarily represent severance and other costs associated with employee terminations, the majority of which have been settled in cash, and totaled approximately $1,050,000. In June 2019, as part of this process, the Company formally communicated the termination of employment to 32 employees, and as of September 30, 2019, the Company had terminated all of these employees. As of December 31, 2019, the Company has paid all obligations related to the restructuring charges.

Other Severance Related Charges

Officer Separation Costs

On June 10, 2019, Frank Amato, the Company’s former Chief Executive Officer, offered his resignation. The Company entered into a Separation Agreement with Mr. Amato, pursuant to which he remained as Chief Executive Officer and a member of the board until September 30, 2019 (the “Separation Date”). Pursuant to the Separation Agreement, Mr. Amato was paid $800,000 on October 1, 2019. In addition, all options to purchase Company common stock held by Mr. Amato continued to vest through the Separation Date and remain exercisable until the one-year anniversary of the Separation Date. All restricted stock units held by Mr. Amato continued to vest through the Separation Date.

Since Mr. Amato provided substantial services to the Company, the Company recognized all costs related to the Separation Agreement over the period from June 10, 2019 to September 30, 2019. In connection with the Separation Agreement, the Company recorded a cash charge of $800,000 for the year ended December 31, 2019.

Additional Executive Separation Costs

Effective July 31, 2019, the Company entered into a Separation Agreement with a former officer. Pursuant to the agreement, a severance payment of $147,500 was recognized and is to be paid evenly over the subsequent six months. As of December 31, 2019, the remaining balance of approximately $25,000 has been accrued.

Subsequent Events

12 Months Ended

Dec. 31, 2019

Subsequent Events [Abstract]

Subsequent Events

Note 22. Subsequent Events

Stock Purchase Agreement with Lincoln Park

On March 27, 2020, the Company and Lincoln Park Capital Fund, LLC (“Lincoln Park”) entered into a purchase agreement pursuant to which the Company has the right to sell to Lincoln Park shares of common stock having an aggregate value of up to $25,000,000, subject to certain significant limitations of the amount and timing of any such sales due to terms and conditions set forth in the purchase agreement.

In consideration for entering into the purchase agreement with Lincoln Park, the Company issued an aggregate of 461,676 shares of common stock to Lincoln Park as a commitment fee. In addition, the Company shall issue to Lincoln Park up to an aggregate of 230,838 additional shares of common stock as a further commitment fee based on a pro-rata percentage of the first $5,000,000 of shares of common stock issued to Lincoln Park under the Purchase Agreement as Purchase Shares (as such term is defined in the purchase agreement with Lincoln Park). The Company will not receive any cash proceeds from the issuance of any of the foregoing commitment shares.

The net proceeds under the purchase agreement to the Company will depend on the frequency and prices at which shares of common stock are sold to Lincoln Park. Actual sales of shares of common stock to Lincoln Park under the purchase agreement and the amount of such net proceeds will depend on a variety of factors, including market conditions, the trading price of the common stock and determinations by the Company as to other available and appropriate sources of funding for the Company. The Company expects to use the proceeds from this agreement for general corporate purposes and working capital.

Changes to Board of Directors

On March 26, 2020, the Company announced the appointments of three new independent members to its Board of Directors effective April 2, 2020. The newly appointed board members are John Gandolfo, Thomas Patton and Peter Cuneo. The Company also announced that current Board members Nick Colucci and Jim Tullis will be stepping down from the Board prior to the Company’s annual meeting of stockholders that is expected to be held in June 2020. Chairman Carrie S. Cox is stepping down from the Board on April 1, 2020 and will be succeeded in that role by independent Board member Michael G. Atieh.

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Basis of Presentation

(a) Basis of Presentation

The accompanying consolidated financial statements were prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”).

Principles of Consolidation

(b) Principles of Consolidation

Use of Estimates

Revenue Recognition

(d) Revenue Recognition

Shipping fees are not billed to the customer and are reflected as part of selling, general, and administrative expenses.

Cash and Cash Equivalents

(e) Cash and Cash Equivalents

Cash and cash equivalents include all highly liquid investments with a maturity of three months or less when purchased.

Marketable Securities

(f) Marketable Securities

Concentration of Credit Risk

(g) Concentration of Credit Risk

Accounts Receivable

(h) Accounts Receivable

Inventories

(i) Inventories

Property and Equipment

(j) Property and Equipment

Depreciation and leasehold improvement amortization is computed using the following estimated useful lives:

Machinery and equipment		3–15 years
Leasehold improvements		Lease term
Furniture and fixtures		5–10 years
Computer equipment		5 years

Leases

(k) Leases

Cloud Computing Arrangement

(l) Cloud Computing Arrangement

Impairment of Long-Lived Assets

(m) Impairment of Long-Lived Assets

Stock Based Compensation

(n) Stock-based Compensation

Income Taxes

(o) Income Taxes

Research and Development

(p) Research and Development

Foreign Currency Translations and Transactions

(q) Foreign Currency Translation and Transactions

Segment Information

(r) Segment Information

Recently Adopted Accounting Pronouncements

(s) Recently Adopted Accounting Pronouncements

Recent Accounting Pronouncements Not Yet Adopted

(t) Recently Accounting Pronouncements Not Yet Adopted

Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Schedule of Property and Equipment, Net

Depreciation and leasehold improvement amortization is computed using the following estimated useful lives:

Machinery and equipment		3–15 years
Leasehold improvements		Lease term
Furniture and fixtures		5–10 years
Computer equipment		5 years

Property and equipment, net, as of December 31, 2019 and 2018 consisted of the following:

	December 31.
	2019			2018
Machinery and equipment	$	393,154		$	424,146
Furniture and fixture		310,820			286,268
Computer equipment and software		20,783			20,783
Leasehold improvements		8,880			—
Property and equipment - gross		733,637			731,197
Less: accumulated depreciation		(388,401	)		(350,293	)
Property and equipment, net	$	345,236		$	380,904

Revenue Recognition (Tables)

12 Months Ended

Dec. 31, 2019

Revenue From Contract With Customer [Abstract]

Summary of Net Sales Disaggregated by Geographic Area

The following table presents net sales disaggregated by geographic area:

	Year ended December 31,
	2019		2018
Geographic Market
United States	$	1,605,814	$	619,772
United Kingdom		665,627		300,091
Germany		102,427		53,784
Other		16,411		19,306
Total Net Sales	$	2,390,279	$	992,953

Cash, Cash Equivalents, and Marketable Securities (Tables)

12 Months Ended

Dec. 31, 2019

Investments Debt And Equity Securities [Abstract]

Summary of Cash, Cash Equivalents, and Marketable Securities

The following tables summarizes the Company’s cash, cash equivalents and marketable securities as of December 31, 2019 and 2018.

As of December 31, 2019
	Amortized Cost		Unrealized Gain		Unrealized (Loss)			Fair Value
Cash and cash equivalents	$	13,564,252	$	—	$	(461	)	$	13,563,791

U.S. Treasury Bonds		10,494,539		811		—			10,495,350
Total marketable securities	$	10,494,539	$	811	$	—		$	10,495,350

Total cash, cash equivalents and marketable securities	$	24,058,791	$	811	$	(461	)	$	24,059,141

As of December 31, 2018
	Amortized Cost		Unrealized Gain		Unrealized (Loss)			Fair Value
Cash and cash equivalents	$	7,600,284	$	—	$	—		$	7,600,284

Corporate Debt Securities	$	18,961,145	$	—	$	(25,888	)	$	18,935,257
Commercial Paper		6,970,867		—		(4,927	)		6,965,940
U.S. Treasury Bonds		35,074,005		—		(12,115	)		35,061,890
Total marketable securities	$	61,006,017	$	—	$	(42,930	)	$	60,963,087

Total cash, cash equivalents and marketable securities	$	68,606,301	$	—	$	(42,930	)	$	68,563,371

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2019

Fair Value Disclosures [Abstract]

Summary of Assets and Liabilities Carried at Fair Value

A summary of the assets and liabilities carried at fair value in accordance with the hierarchy defined above is as follows:

			Fair Value Hierarchy
December 31, 2019	Total		(Level 1)		(Level 2)		(Level 3)
Assets
Cash and cash equivalents	$	13,563,791	$	13,563,791	$	—	$	—
Marketable Securities:
U.S. Treasury Bonds		10,495,350		10,495,350		—		—
Total	$	24,059,141	$	24,059,141	$	—	$	—

December 31, 2018
Assets
Cash and cash equivalents	$	7,600,284	$	7,600,284	$	—	$	—
Marketable Securities:
Corporate Debt Securities		18,935,257		18,935,257		—		—
Commercial Paper		6,965,940		6,965,940		—		—
U.S. Treasury Bonds		35,061,890		35,061,890		—		—
Total	$	68,563,371	$	68,563,371	$	—	$	—

Inventory (Tables)

12 Months Ended

Dec. 31, 2019

Inventory Disclosure [Abstract]

Inventories Stated at Lower of Cost or Market

As of December 31, 2019 and 2018, inventories consisted of the following:

	December 31,
	2019		2018
Raw materials	$	1,065,345	$	821,704
Work in process		5,314,763		951,695
Finished Goods		531,064		176,003
Total Inventory		6,911,172		1,949,402
Less: noncurrent inventory		6,020,180		—
Total current inventory	$	890,992	$	1,949,402

Property and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2019

Property Plant And Equipment [Abstract]

Schedule of Property and Equipment, Net

Depreciation and leasehold improvement amortization is computed using the following estimated useful lives:

Machinery and equipment		3–15 years
Leasehold improvements		Lease term
Furniture and fixtures		5–10 years
Computer equipment		5 years

Property and equipment, net, as of December 31, 2019 and 2018 consisted of the following:

	December 31.
	2019			2018
Machinery and equipment	$	393,154		$	424,146
Furniture and fixture		310,820			286,268
Computer equipment and software		20,783			20,783
Leasehold improvements		8,880			—
Property and equipment - gross		733,637			731,197
Less: accumulated depreciation		(388,401	)		(350,293	)
Property and equipment, net	$	345,236		$	380,904

Leases (Tables)

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Supplemental Balance Sheet Information for Operating Leases

Supplemental Balance Sheet Information for Operating Leases:

	December 31, 2019
Operating leases:
Operating lease right of use assets	$	1,430,641
Operating lease liabilities:
Current portion of operating lease liabilities		486,445
Noncurrent operating lease liabilities		1,419,880
Total operating lease liabilities	$	1,906,325
Weighted average remaining lease term (in years)		5.9
Weighted average discount rate		13.75	%

Supplemental Statement of Cash Flows Information for Operating Leases

Supplemental Statement of Cash Flows Information for Operating Leases:

	For the year ended December 31, 2019
Noncash lease expense		315,458
Change in operating lease liabilities		(257,678	)

Future Minimum Lease Payments under Non-Cancellable Operating Leases

Future minimum lease payments under non-cancellable operating leases as of December 31, 2019:

Financial year
2020	$	712,076
2021		690,358
2022		337,254
2023		142,892
2024		146,044
2025 and thereafter		676,260
Total future minimum lease payments		2,704,884
Less: Amounts representing interest		(798,559	)
Total	$	1,906,325

Schedule of Future Minimum Lease Payments Under Non-Cancelable Operating leases

Financial year
2019	$	576,743
2020		714,616
2021		692,893
2022		737,324
2023 and thereafter		3,696,796
Total	$	6,418,372

Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2019

Payables And Accruals [Abstract]

Schedule of Accrued Expenses

Accrued expenses as of December 31, 2019 and 2018 consisted of the following:

	December 31,
	2019		2018
Accrued professional fees	$	1,255,494	$	1,273,249
Accrued bonuses		804,082		2,152,264
Other accrued expenses		1,277,803		948,588
	$	3,337,379	$	4,374,101

Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2019

Earnings Per Share [Abstract]

Schedule of Common Stock Equivalents Excluded from Computation of Diluted Loss per Share

The potential common stock equivalents that have been excluded from the computation of diluted loss per share consist of the following:

	December 31,
	2019		2018
Outstanding stock options		3,131,266		2,228,904
Nonvested restricted stock and unit awards		1,368,998		265,569
Stock purchase warrants		62,181		—

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Reconciliation of Income Tax Provision Computed at Statutory Rates

A reconciliation of the income tax provision computed at statutory rates to the reported income tax provision for the years ended December 31, 2019 and 2018 is as follows:

	Year ended December 31,
	2019	2018
Statutory rate	21.0%	21.0%
State tax expected (recovery), net of federal benefit	6.7%	2.6%
Nondeductible expenses	(0.13)%	(2.9)%
Loss incurred as pass-through	—%	(7.9)%
Change in valuation allowance for deferred tax assets	(27.6)%	(12.8)%
Provision for income taxes	(0.04)%	—%

Components of Deferred Income Tax Assets and Liabilities

The net change in the valuation allowance was an increase of $12.4 million.

The significant components of the Company’s deferred income tax assets and liabilities after applying enacted corporate tax rates are as follows:

	Year ended December 31,
	2019			2018
Deferred tax assets
Net operating loss carryforwards	$	18,883,686		$	7,578,570
Accrued expenses		796,849			735,910
Intangibles		355,288			290,098
Inventory		78,206			66,935
Deferred rent		—			65,574
Charitable contributions		19,028			10,602
R&D credit		394,981			—
Lease liabilities		518,480			—
Stock compensation		750,449			—
Deferred tax assets		21,796,967			8,747,689
Less valuation allowance		(21,171,967	)		(8,722,389	)
Total deferred tax assets		625,000			25,300
Fixed assets		(15,222	)		(25,300	)
Prepaid expenses		(220,673	)		—
Right of use asset		(389,105	)		—
Total deferred tax liabilities		(625,000	)		(25,300	)
Deferred tax assets, net	$	—		$	—

Components of Loss Before Provision For Income Taxes Domestic and Foreign

Domestic and foreign components of loss before provision for income taxes is as follows:

	December 31, 2019			December 31, 2018
Domestic	$	(43,661,897	)	$	(55,268,310	)
Foreign		(1,468,287	)		(494,714	)
Total	$	(45,130,184	)	$	(55,763,024	)

Schedule of Income Tax Provision From Continuing Operations

The income tax provision from continuing operations contains the following components:

	December 31, 2019		December 31, 2018
Federal	$	—	$	—
State	$	7,712	$	2,431
Foreign	$	9,987	$	—
Total current		17,699		2,431

Total deferred		—		—
Total income tax expense/(benefit)	$	17,699	$	2,431

Stock Compensation and Unit-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2019

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Summary of Stock Options Granted Activity

The following table presents a summary of stock options granted:

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding, December 31, 2018		2,228,904		$	14.89		9.5	*
Granted		2,146,699			4.68
Exercised		—			—
Cancelled		(1,244,337	)		13.34
Outstanding, December 31, 2019		3,131,266		$	8.53		8.9	*
Exercisable, December 31, 2019		1,348,994		$	11.99		8.6	*

* de minimis

Summary of Additional Information about Stock Options

The following table provides additional information about stock options that are outstanding and exercisable at December 31, 2019:

Exercise Price	Options Outstanding		Weighted Average Remaining Contractual Life (Years)		Options Exercisable
$1.40 - $2.50		1,019,495		9.7		95,635
$2.51 - $7.52		647,629		9.2		324,900
$7.53 - $15.00		1,464,142		8.6		928,459

Summary of Restricted Stock Awards Granted Activity

The following table presents a summary of restricted stock awards granted:

	Number of Shares			Weighted Average Grant Date Fair Value
Nonvested, December 31, 2018		185,571		$	15.00
Granted		204,088			6.88
Vested		(139,473	)		14.25
Cancelled		(122,681	)		9.27
Nonvested, December 31, 2019		127,505		$	8.09

Summary of Restricted Stock and Deferred Stock Units Granted Activity

The following table presents a summary of restricted and deferred stock units (“Stock Units”) granted:

	Number of Shares			Weighted Average Grant Date Fair Value
Nonvested, December 31, 2018		79,998		$	15.00
Granted		1,566,205			2.47
Vested		(274,939	)		4.62
Cancelled		(129,771	)		1.90
Nonvested, December 31, 2019		1,241,493		$	2.86

Summary of Weighted Average Assumptions Used in Valuing Plans

The weighted average assumptions used in the Black-Scholes option pricing model in valuing stock options granted in the periods presented were:

	2019		2018
Fair value at grant date	$	3.39	$	2.50
Expected volatility	95.9%		70.9%
Risk-free interest rate	2.1%		2.7%
Expected holding period, in years		5.9		5.9
Dividend yield		—		—

2019 Employee Stock Purchase Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Summary of Weighted Average Assumptions Used in Valuing Plans

The weighted average assumptions used in the Black-Scholes valuation of the fair value of the discount for the year ended December 31, 2019 were:

	2019
Fair value at grant date	$	0.75
Expected volatility	169%
Risk-free interest rate	2.3%
Expected holding period	6 months
Dividend yield		—

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2019

Commitments And Contingencies Disclosure [Abstract]

Schedule of Warrants Issued

# Warrants		Exercise Price		Expiration Date
	8,576	$	8.86	April 1, 2021
	22,253	$	5.68	March 30, 2022
	17,066	$	12.60	June 30, 2022
	14,286	$	12.60	August 31, 2022

Business - Additional Information (Details) - USD ($)	1 Months Ended	12 Months Ended
Business - Additional Information (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2019	Dec. 31, 2018
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Entity information, date to change former legal or registered name		Jun. 21, 2018
Net proceeds from issuance of common stock after deducting underwriting discounts and commissions and offering costs			$ 78,334,457
Common Stock
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Common stock, shares issued			5,980,000
IPO
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Net proceeds from issuance of common stock after deducting underwriting discounts and commissions and offering costs	$ 77,500,000
Underwriting discounts and commissions and offering costs	$ 12,200,000
IPO \| Common Stock
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Common stock, shares issued	5,980,000
Common stock, issue price per share	$ 15.00

Significant Accounting Policies - Additional Information (Details)	12 Months Ended
	Dec. 31, 2019 Segment
Accounting Policies [Line Items]
Revenue performance obligation, description of payment terms	Trade credits are discounts that are contingent upon a timely remittance of payment and are estimated based on historical experience. Damaged or defective products are replaced at no charge under the Company’s standard warranty. A cash refund is allowed under specific circumstances for undamaged and non-defective returned products.
Number of operating segment	1
Leasehold Improvements
Accounting Policies [Line Items]
Property and equipment, estimated useful lives	lesser of the lease terms or the estimated useful lives of the assets.

Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Leasehold improvements	Lease term
Machinery and Equipment \| Minimum
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	3 years
Machinery and Equipment \| Maximum
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	15 years
Furniture and Fixtures \| Minimum
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	5 years
Furniture and Fixtures \| Maximum
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	10 years
Computer Equipment
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	5 years

Significant Risks and Uncertainties - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Risks And Uncertainties [Abstract]
Net losses	$ 45,147,883	$ 55,765,455
Accumulated deficit	$ 83,479,098	$ 38,331,215

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686

+ Details

Revenue Recognition - Summary of Net Sales Disaggregated by Geographic Area (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Disaggregation Of Revenue [Line Items]
Total Net Sales	$ 2,390,279	$ 992,953
United States
Disaggregation Of Revenue [Line Items]
Total Net Sales	1,605,814	619,772
United Kingdom
Disaggregation Of Revenue [Line Items]
Total Net Sales	665,627	300,091
Germany
Disaggregation Of Revenue [Line Items]
Total Net Sales	102,427	53,784
Other
Disaggregation Of Revenue [Line Items]
Total Net Sales	$ 16,411	$ 19,306

Revenue Recognition - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Mar. 01, 2020	Feb. 01, 2019
Disaggregation Of Revenue [Line Items]
Revenue remaining unsatisfied performance obligation	$ 0
Payment term for customers	120 days
Subsequent Event
Disaggregation Of Revenue [Line Items]
Maximum amount of reduction in monthly co-payments of each prescription		$ 100
Maximum
Disaggregation Of Revenue [Line Items]
Amount of reduction patients could receive from cost of co-payments of first month of therapy			$ 300
Amount of reduction from the cost of each refill for maximum of 12 months			$ 250

Cash, Cash Equivalents, and Marketable Securities - Summary of Cash, Cash Equivalents, and Marketable Securities (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Schedule Of Available For Sale Securities [Line Items]
Cash and Cash Equivalents, Amortized Cost	$ 13,564,252	$ 7,600,284
Cash and Cash Equivalents, Unrealized (Loss)	(461)
Cash and cash equivalents	13,563,791	7,600,284
Marketable securities, Amortized Cost	10,494,539	61,006,017
Marketable securities, Unrealized Gain	811
Marketable securities, Unrealized (Loss)		(42,930)
Marketable securities, Fair Value	10,495,350	60,963,087
Cash, cash equivalents and marketable securities, Amortized Cost	24,058,791	68,606,301
Cash, cash equivalents and marketable securities, Unrealized Gain	811
Cash, cash equivalents and marketable securities, Unrealized (Loss)	(461)	(42,930)
Cash, cash equivalents and marketable securities, Fair Value	24,059,141	68,563,371
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost		18,961,145
Marketable securities, Unrealized (Loss)		(25,888)
Marketable securities, Fair Value		18,935,257
Cash, cash equivalents and marketable securities, Fair Value		18,935,257
Commercial Paper
Schedule Of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost		6,970,867
Marketable securities, Unrealized (Loss)		(4,927)
Marketable securities, Fair Value		6,965,940
Cash, cash equivalents and marketable securities, Fair Value		6,965,940
U.S. Treasury Bonds
Schedule Of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost	10,494,539	35,074,005
Marketable securities, Unrealized Gain	811
Marketable securities, Unrealized (Loss)		(12,115)
Marketable securities, Fair Value	10,495,350	35,061,890
Cash, cash equivalents and marketable securities, Fair Value	$ 10,495,350	$ 35,061,890

Fair Value Measurements - Summary of Assets and Liabilities Carried at Fair Value (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 13,563,791	$ 7,600,284
Marketable Securities	24,059,141	68,563,371
Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable Securities		18,935,257
U.S. Treasury Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable Securities	10,495,350	35,061,890
Commercial Paper
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable Securities		6,965,940
(Level 1)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents	13,563,791	7,600,284
Marketable Securities	24,059,141	68,563,371
(Level 1) \| Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable Securities		18,935,257
(Level 1) \| U.S. Treasury Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable Securities	$ 10,495,350	35,061,890
(Level 1) \| Commercial Paper
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable Securities		$ 6,965,940

Fair Value Measurements - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Fair value of assets, transfer from level 1 to level 2	$ 0	$ 0
Fair value of assets transfer from level 2 to level 1	0	0
Fair value of liabilities, transfer from level 1 to level 2	0	0
Fair value of liabilities, transfer from level 2 to level 1	0	0
Fair value of assets, transfers into level 3	0	0
Fair value of assets, transfers out of level 3	0	0
Fair value of liabilities, transfers Into level 3	0	0
Fair value of liabilities, transfers out of level 3	$ 0	$ 0

Inventory - Inventories Stated at Lower of Cost or Market (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 1,065,345	$ 821,704
Work in process	5,314,763	951,695
Finished Goods	531,064	176,003
Total Inventory	6,911,172	1,949,402
Inventories, noncurrent	6,020,180
Total current inventory	$ 890,992	$ 1,949,402

Inventory - Additional Information (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Inventory [Line Items]
Noncurrent inventory raw materials	$ 1,000,000
Noncurrent inventory work in process	5,000,000
Inventory Valuation and Obsolescence [Member]
Inventory [Line Items]
Inventory raw materials	$ 287,544	$ 147,450

Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 733,637	$ 731,197
Less: accumulated depreciation	(388,401)	(350,293)
Property and equipment, net	345,236	380,904
Machinery and Equipment
Property Plant And Equipment [Line Items]
Property and equipment - gross	393,154	424,146
Furniture and Fixture
Property Plant And Equipment [Line Items]
Property and equipment - gross	310,820	286,268
Computer Equipment and Software
Property Plant And Equipment [Line Items]
Property and equipment - gross	20,783	$ 20,783
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 8,880

Property and Equipment, Net - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Property Plant And Equipment [Line Items]
Depreciation	$ 108,546	$ 66,663
Fully Depreciated Assets
Property Plant And Equipment [Line Items]
Write-off of assets	$ 70,639
Fully Depreciated Assets \| Bermuda \| Subsidiary
Property Plant And Equipment [Line Items]
Write-off of assets		295,384
Fully Depreciated Assets \| Australian \| Affiliate
Property Plant And Equipment [Line Items]
Write-off of assets		$ 295,384

Leases - Additional Information (Details) - USD ($)	12 Months Ended
Leases - Additional Information (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018	Jan. 01, 2019	Nov. 01, 2018
Lessee Lease Description [Line Items]
Right of use assets recognized for leases	$ 1,430,641
Lease liabilities	$ 1,906,325		$ 4,200,000
Effective date	Jan. 01, 2019
Remaining lease term	12 months or less
Lease option to extend	up to an additional five years
Lessee, operating lease, incremental borrowing rate	13.75%			9.75%
Recognized lease expenses	$ 787,952	$ 496,055
Total lease expense, in accordance with superseded lease standard		$ 496,055
Minimum
Lessee Lease Description [Line Items]
Lease, Term of contract	3 years
Maximum
Lessee Lease Description [Line Items]
Lease, Term of contract	5 years
Lessee, operating lease, extension term	5 years
Building
Lessee Lease Description [Line Items]
Right of use assets recognized for leases			$ 3,900,000

Leases - Supplemental Balance Sheet Information for Operating Leases (Details) - USD ($)	Dec. 31, 2019	Jan. 01, 2019	Nov. 01, 2018
Operating leases:
Operating lease right of use assets	$ 1,430,641
Current portion of operating lease liabilities	486,445
Noncurrent operating lease liabilities	1,419,880
Total operating lease liabilities	$ 1,906,325	$ 4,200,000
Weighted average remaining lease term (in years)	5 years 10 months 24 days
Weighted average discount rate	13.75%		9.75%

Leases - Supplemental Statement of Cash Flows Information for Operating Leases (Details)	12 Months Ended
	Dec. 31, 2019 USD ($)
Leases [Abstract]
Noncash lease expense	$ 315,458
Change in operating lease liabilities	$ (257,678)

Leases - Future Minimum Lease Payments under Non-Cancellable Operating Leases (Details) - USD ($)	Dec. 31, 2019	Jan. 01, 2019
Leases [Abstract]
2020	$ 712,076
2021	690,358
2022	337,254
2023	142,892
2024	146,044
2025 and thereafter	676,260
Total future minimum lease payments	2,704,884
Less: Amounts representing interest	(798,559)
Total	$ 1,906,325	$ 4,200,000

Leases - Schedule of Future Minimum Lease Payments Under Non-Cancelable Operating leases (Details)	Dec. 31, 2018 USD ($)
Leases [Abstract]
2019	$ 576,743
2020	714,616
2021	692,893
2022	737,324
2023 and thereafter	3,696,796
Total	$ 6,418,372

Cloud Computing Arrangement - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cloud Computing Arrangement [Abstract]
Cloud computing arrangement implementation cost incurred	$ 826,918	$ 395,404
Amortization of deferred costs	$ 141,037

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Accrued Liabilities Current [Abstract]
Accrued professional fees	$ 1,255,494	$ 1,273,249
Accrued bonuses	804,082	2,152,264
Other accrued expenses	1,277,803	948,588
Accrued expenses	$ 3,337,379	$ 4,374,101

Note Payable - Additional Information (Details) - USD ($)		12 Months Ended
	Jul. 01, 2019	Dec. 31, 2019
Notes Payable [Line Items]
Proceeds from borrowings	$ 807,347	$ 807,347
Notes payable remaining balance		$ 111,878
Debt instrument balance fully paid		2020-01
Note Payable
Notes Payable [Line Items]
Debt instrument, term	7 months
Debt instrument, annual interest rate	2.99%
Interest expense		$ 3,457

Net Loss Per Share - Additional Information (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Net loss per share	$ (1.54)	$ (1.19)
ElectroCore, Inc
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Net loss per share		$ 1.19

Net Loss Per Share - Schedule of Common Stock Equivalents Excluded from Computation of Diluted Loss per Share (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Outstanding stock options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	3,131,266	2,228,904
Nonvested restricted stock and unit awards
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	1,368,998	265,569
Stock purchase warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	62,181

Corporate Conversion and Equity - Additional Information (Details)		12 Months Ended			18 Months Ended
	Jun. 20, 2018 USD ($) Unit	Dec. 31, 2019 USD ($) $ / shares shares	Dec. 31, 2018 $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2019 USD ($) Vote $ / shares shares	Jun. 30, 2018 $ / shares	Jun. 21, 2018 $ / shares shares	Mar. 31, 2018 shares
Class of Stock [Line Items]
Common stock, shares authorized		500,000,000	500,000,000		500,000,000		500,000,000
Preferred stock, shares authorized		10,000,000	10,000,000		10,000,000		10,000,000
Common stock, par value \| $ / shares		$ 0.001	$ 0.001		$ 0.001		$ 0.001
Preferred stock, par value \| $ / shares		$ 0.001	$ 0.001		$ 0.001		$ 0.001
Common stock, shares issued		29,835,183	29,450,035		29,835,183
Preferred stock, shares issued		0	0		0		0
Number of classes of units permitted for issuance \| Unit	4
Number of vote each member is entitled to for each unit held \| Vote					1
Warrants issued to purchase of stock								7,739,092
Financial Advisors
Class of Stock [Line Items]
Warrants to purchase common stock				101,119
Exercise price of warrants \| $ / shares				$ 12.60
Purchasers of Bridge Notes
Class of Stock [Line Items]
Warrants to purchase common stock							429,948
Exercise price of warrants \| $ / shares							$ 12.60
Series A Preferred Units
Class of Stock [Line Items]
Accrued and unpaid preferred return payable \| $		$ 3,600,000			$ 3,600,000
Total convertible preferred units \| $	$ 54,923,430			$ 53,518,463
Preferred return percentage		4.00%
Reduction in preferred return percentage		2.00%
Stock split, conversion ratio		0.05556
Warrants issued to purchase of stock			0
Series A Preferred Units \| December 2015 Term Loan \| Financial Advisors
Class of Stock [Line Items]
Warrants issued to purchase of stock			221,766
Series B Preferred Units
Class of Stock [Line Items]
Total convertible preferred units \| $				68,755,544
Stock split, conversion ratio		0.05556
Series B Preferred Units \| Purchase Agreement
Class of Stock [Line Items]
Proceeds from issuance of preferred stock \| $				46,911,300
Aggregate amount of bridge notes and related accrued and unpaid interest \| $				73,630,210
Aggregate amount of bridge notes and related accrued and unpaid interest \| $				73,630,210
Series B Preferred Units \| Promissory Notes \| Purchase Agreement
Class of Stock [Line Items]
Bridge note converted amount \| $				$ 26,718,910
Common Stock
Class of Stock [Line Items]
Units converted into common stock shares					23,470,035
Preferred return payable upon public offering \| $	$ 3,629,092
Warrants issued to purchase of stock		35,452,084			35,452,084
Exercise price of warrants \| $ / shares		$ 1.25			$ 1.25
Common Stock \| Advisors
Class of Stock [Line Items]
Warrants issued to purchase of stock							2,724,549
Warrants to purchase common stock							151,364
Exercise price of warrants \| $ / shares							$ 12.60
Common Stock \| Advisors \| Exercise Price One
Class of Stock [Line Items]
Warrants issued to purchase of stock		2,724,549			2,724,549
Exercise price of warrants \| $ / shares		$ 0.70			$ 0.70
Common Stock \| Advisors \| Exercise Price Two
Class of Stock [Line Items]
Warrants issued to purchase of stock		72,000			72,000
Exercise price of warrants \| $ / shares		$ 1.25			$ 1.25
Common Stock \| Profits Interests
Class of Stock [Line Items]
Units converted into common stock shares		1,345,231	1,345,231		1,345,231
Options to purchase common stock shares		2,141,748
Options to purchase common stock shares, exercise price \| $ / shares		$ 15.00			$ 15.00
Common Stock \| Common Units
Class of Stock [Line Items]
Units converted into common stock shares					12,099,280
Common Stock \| Series A Preferred Units
Class of Stock [Line Items]
Units converted into common stock shares					4,181,856
Common stock shares issued as payment in full for accrued and unpaid preferred return payable		241,939			241,939
Common Stock \| Series B Preferred Units
Class of Stock [Line Items]
Units converted into common stock shares					5,843,668
IPO
Class of Stock [Line Items]
Common stock, shares issued							29,450,035
IPO \| Common Stock
Class of Stock [Line Items]
Options to purchase common stock shares, exercise price \| $ / shares						$ 15.00
IPO \| Common Stock \| Profits Interests
Class of Stock [Line Items]
Units converted into common stock shares		62,765,605
IPO \| Common Stock \| Series A Warrants
Class of Stock [Line Items]
Warrants to purchase common stock			12,321
Exercise price of warrants \| $ / shares			$ 15.30

Variable Interest Entity - Additional Information (Details) - ElectroCore (Aust) Pty Limited	12 Months Ended
	Dec. 31, 2019 Director
Variable Interest Entity [Line Items]
Variable interest entity ownership percentage	50.00%
Number of directors	4
Number of directors appoint	2

Income Taxes - Reconciliation of Income Tax Provision Computed at Statutory Rates (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Statutory rate	21.00%	21.00%
State tax expected (recovery), net of federal benefit	6.70%	2.60%
Nondeductible expenses	(0.13%)	(2.90%)
Loss incurred as pass-through		(7.90%)
Change in valuation allowance for deferred tax assets	(27.60%)	(12.80%)
Provision for income taxes	(0.04%)

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Line Items]
Net change in valuation allowance	$ 12,400,000
Net operating loss carryforwards	$ 18,883,686	$ 7,578,570
Period for cumulative change in ownership	3 years
Cumulative change in ownership percentage	50.00%
Operating loss carryforwards, limitations on use	NOL carryforwards may be, or become subject to, an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, as well as similar state tax provisions. This could limit the amount of NOLs that the Company can utilize annually to offset future taxable income or tax liabilities. The amount of the annual limitation, if any, will be determined based on the value of the Company immediately prior to an ownership change. Subsequent ownership changes may further affect the limitation in future years. If and when the Company utilizes the NOL carryforwards in a future period, it will perform an analysis to determine the effect, if any, of these loss limitation rules on the NOL carryforward balances.
Accruals relating to uncertain tax position	$ 0
Germany
Income Tax Disclosure [Line Items]
Accumulated non-capital losses	3,500,000	3,700,000
United States
Income Tax Disclosure [Line Items]
Net operating loss carryforwards	$ 65,700,000	$ 24,600,000

Income Taxes - Components of Deferred Income Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Deferred tax assets
Net operating loss carryforwards	$ 18,883,686	$ 7,578,570
Accrued expenses	796,849	735,910
Intangibles	355,288	290,098
Inventory	78,206	66,935
Deferred rent		65,574
Charitable contributions	19,028	10,602
R&D credit	394,981
Lease liabilities	518,480
Stock compensation	750,449
Deferred tax assets	21,796,967	8,747,689
Less valuation allowance	(21,171,967)	(8,722,389)
Total deferred tax assets	625,000	25,300
Fixed assets	(15,222)	(25,300)
Prepaid expenses	(220,673)
Right of use asset	(389,105)
Total deferred tax liabilities	$ (625,000)	$ (25,300)

Income Taxes - Components of Loss Before Provision For Income Taxes Domestic and Foreign (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Domestic	$ (43,661,897)	$ (55,268,310)
Foreign	(1,468,287)	(494,714)
Loss before income taxes	$ (45,130,184)	$ (55,763,024)

Income Taxes - Schedule of Income Tax Provision From Continuing Operations (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
State	$ 7,712	$ 2,431
Foreign	9,987
Total current	17,699	2,431
Total income tax expense/(benefit)	$ 17,699	$ 2,431

Warrant Liability - Additional Information (Details) - $ / shares	Jun. 21, 2018	Mar. 31, 2018
Debt Instrument [Line Items]
Warrants issued to purchase of stock		7,739,092
Purchasers of Bridge Notes
Debt Instrument [Line Items]
Warrants to purchase common stock	429,948
Exercise price of warrants	$ 12.60

Stock Compensation and Unit-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions				12 Months Ended		18 Months Ended
	Jan. 01, 2019	Jun. 21, 2018	Jun. 20, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unit-based compensation, additional vesting period				3 years
Number of units, granted				2,146,699
Options initial exercise price				$ 8.53	$ 14.89	$ 8.53
Fair market value per share of common stock				$ 1.59		$ 1.59
Unrecognized compensation cost related to equity awards				$ 7.9		$ 7.9
Unrecognized compensation expected to be recognized				3 years
Selling, General and Administrative Expense
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock compensation expense				$ 2.7	$ 4.6
Research and Development Expense
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock compensation expense				1.1	2.8
Cost of Goods Sold
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock compensation expense				$ 0.1	$ 0.2
Employees and Consultants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period				4 years
Non-employee Director
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period				12 months
2018 Omnibus Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Plan terms				On June 21, 2018, the Company adopted the 2018 Omnibus Equity Incentive Plan (“Plan”). This plan reserved 6.2 million shares with an increase to be added annually beginning in 2019 through 2028 up to 4% of the total number of shares of common stock issued and outstanding on a fully diluted basis as of the end of the immediately preceding fiscal year, providing that the aggregate number of additional shares shall not exceed a total of 45 million shares, and a maximum of 40 million shares pursuant to the exercise of stock options.
Shares reserved for future issuance	6,900,000	6,200,000
Maximum number of shares issuable under the plan, in proportion to common stock, percentage		4.00%
Stock options, contractual life		10 years
Number shares available to be awarded under the plan				2,120,000		2,120,000
2018 Omnibus Equity Incentive Plan \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum number additional shares allowed under the plan		45,000,000
Maximum number additional shares allowed pursuant to exercise of stock options under the plan		40,000,000
Restricted Stock Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Awards, outstanding				1,345,231	185,571	1,345,231
Awards, forfeited					2,521
Awards, granted					0
Restricted Stock Awards \| Employees and Consultants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period				4 years
Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period				2 years
2019 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares reserved	300,000
2019 Employee Stock Purchase Plan \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum number additional shares allowed under the plan	4,500,000
Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Units issued converted into common stock shares						23,470,035
Stock compensation expense not yet recognized				$ 7.8		$ 7.8
Common Stock \| Common Stock Awards that Vest at the Time of Issuance
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock compensation expense not yet recognized				3.8		3.8
Common Stock \| Common Stock Awards that Did Not Vest Immediately
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock compensation expense not yet recognized				0.4		0.4
Common Stock \| Options to Purchase Common Stock that Did Not Vest Immediately
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock compensation expense not yet recognized				$ 3.6		$ 3.6
Profits Interests
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of units, granted					19,447,218
Number of units, forfeited			110,354
Options initial exercise price				$ 15.00		$ 15.00
Profits Interests \| Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Units issued converted into common stock shares				1,345,231	1,345,231	1,345,231
Options to purchase common stock shares				2,141,748
Options initial exercise price				$ 15.00		$ 15.00
Profits Interests \| Common Stock \| IPO
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Units issued converted into common stock shares				62,765,605
Stock compensation expense not yet recognized				$ 2.8		$ 2.8
Profits Interests \| Common Stock \| IPO \| Common Stock Awards that Vest at the Time of Issuance
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock compensation expense not yet recognized				1.2		1.2
Profits Interests \| Common Stock \| IPO \| Common Stock Awards that Did Not Vest Immediately
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock compensation expense not yet recognized				0.2		0.2
Profits Interests \| Common Stock \| IPO \| Options to Purchase Common Stock that Did Not Vest Immediately
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock compensation expense not yet recognized				$ 1.4		$ 1.4
One Year Anniversary
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unit-based compensation, vesting rights percentage				25.00%
Options Vested Immediately \| Profits Interests
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of vested stock option				1,157,139
Options Vesting of 25% on January 1, 2019 and Balance Over Next Succeeding 10 Calendar Quarters \| Profits Interests
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of vested stock option				188,092
Options Vesting on January 1, 2019 \| Profits Interests
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unit-based compensation, vesting rights percentage				100.00%
Number of vested stock option				228,954
Options Vesting 25% on January 1, 2019, Remaining Vesting Over The Next 14 Quarters \| Profits Interests
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unit-based compensation, vesting rights percentage				25.00%
Number of vested stock option				1,912,797

Stock Compensation and Unit-Based Compensation - Summary of Stock Options Granted Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Options, Outstanding, December 31, 2018	3,131,266	2,228,904
Number of Options, Granted	2,146,699
Number of Options, Cancelled	(1,244,337)
Number of Options, Exercisable, December 31, 2019	1,348,994
Weighted Average Exercise Price, Outstanding, December 31, 2018	$ 8.53	$ 14.89
Weighted Average Exercise Price, Granted	4.68
Weighted Average Exercise Price, Cancelled	13.34
Weighted Average Exercise Price, Exercisable, December 31, 2019	$ 11.99
Weighted Average Remaining Contractual Term (Years), Outstanding, December 31, 2018	8 years 10 months 24 days	9 years 6 months
Weighted Average Remaining Contractual Term (Years), Exercisable, December 31, 2019	8 years 7 months 6 days

Stock Compensation and Unit-Based Compensation - Summary of Additional Information about Stock Options (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options Outstanding	3,131,266	2,228,904
Weighted Average Remaining Contractual Term (Years), Outstanding, December 31, 2018	8 years 10 months 24 days	9 years 6 months
Options Exercisable	1,348,994
Exercise Price $1.40 - $2.50
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise Price	$ 1.40
Exercise Price	$ 2.50
Options Outstanding	1,019,495
Weighted Average Remaining Contractual Term (Years), Outstanding, December 31, 2018	9 years 8 months 12 days
Options Exercisable	95,635
Exercise Price $2.51 - $7.52
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise Price	$ 2.51
Exercise Price	$ 7.52
Options Outstanding	647,629
Weighted Average Remaining Contractual Term (Years), Outstanding, December 31, 2018	9 years 2 months 12 days
Options Exercisable	324,900
Exercise Price $7.53 - $15.00
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise Price	$ 7.53
Exercise Price	$ 15.00
Options Outstanding	1,464,142
Weighted Average Remaining Contractual Term (Years), Outstanding, December 31, 2018	8 years 7 months 6 days
Options Exercisable	928,459

Stock Compensation and Unit-Based Compensation - Summary of Restricted Stock Awards Granted Activity (Details) - Restricted Stock Awards	12 Months Ended
	Dec. 31, 2019 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Nonvested, December 31, 2018 \| shares	185,571
Number of Shares, Granted \| shares	204,088
Number of Shares, Vested \| shares	(139,473)
Number of Shares, Cancelled \| shares	(122,681)
Number of Shares, Nonvested, December 31, 2019 \| shares	127,505
Weighted Average Grand Date Fair Value, Nonvested, December 31, 2018 \| $ / shares	$ 15.00
Weighted Average Grand Date Fair Value, Granted \| $ / shares	6.88
Weighted Average Grand Date Fair Value, Vested \| $ / shares	14.25
Weighted Average Grand Date Fair Value, Cancelled \| $ / shares	9.27
Weighted Average Grand Date Fair Value, Nonvested, December 31, 2019 \| $ / shares	$ 8.09

Stock Compensation and Unit-Based Compensation - Summary of Restricted Stock and Deferred Stock Units Granted Activity (Details) - Stock Units	12 Months Ended
	Dec. 31, 2019 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Nonvested, December 31, 2018 \| shares	79,998
Number of Shares, Granted \| shares	1,566,205
Number of Shares, Vested \| shares	(274,939)
Number of Shares, Cancelled \| shares	(129,771)
Number of Shares, Nonvested, December 31, 2019 \| shares	1,241,493
Weighted Average Grand Date Fair Value, Nonvested, December 31, 2018 \| $ / shares	$ 15.00
Weighted Average Grand Date Fair Value, Granted \| $ / shares	2.47
Weighted Average Grand Date Fair Value, Vested \| $ / shares	4.62
Weighted Average Grand Date Fair Value, Cancelled \| $ / shares	1.90
Weighted Average Grand Date Fair Value, Nonvested, December 31, 2019 \| $ / shares	$ 2.86

Stock Compensation and Unit-Based Compensation - Summary of Weighted Average Assumptions Used in Valuing Plans (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value at grant date	$ 3.39	$ 2.50
Expected volatility	95.90%	70.90%
Risk-free interest rate	2.10%	2.70%
Expected holding period, in years	5 years 10 months 24 days	5 years 10 months 24 days
2019 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value at grant date	$ 0.75
Expected volatility	169.00%
Risk-free interest rate	2.30%
Expected holding period, in years	6 months

Employee Benefit Plan - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Compensation And Retirement Disclosure [Abstract]
Defined contribution plan, sponsor location [Extensible list]	country:US	country:US
Defined contribution plan, plan name	401(k)
Employer contributions	$ 0	$ 0

Commitments and Contingencies - Additional Information (Details) - USD ($)	1 Months Ended
	Jan. 31, 2019	Dec. 31, 2019
Class Of Warrant Or Right [Line Items]
Purchase obligations		$ 1,700,000
Common Stock
Class Of Warrant Or Right [Line Items]
Exercise price of warrants		$ 1.25
Former Financial Advisor
Class Of Warrant Or Right [Line Items]
Cash paid in settlement agreement	$ 325,000
Former Financial Advisor \| Common Stock
Class Of Warrant Or Right [Line Items]
Warrants to purchase common stock	62,181
Former Financial Advisor \| Common Stock \| Minimum
Class Of Warrant Or Right [Line Items]
Exercise price of warrants	$ 5.68
Former Financial Advisor \| Common Stock \| Maximum
Class Of Warrant Or Right [Line Items]
Exercise price of warrants	$ 12.60

Commitments and Contingencies - Schedule of Warrants Issued (Details) - $ / shares	Jan. 31, 2019	Mar. 31, 2018
Class Of Warrant Or Right [Line Items]
Number of Warrants		7,739,092
Former Financial Advisor \| Warrant One
Class Of Warrant Or Right [Line Items]
Number of Warrants	8,576
Exercise Price	$ 8.86
Expiration Date	Apr. 01, 2021
Former Financial Advisor \| Warrant Two
Class Of Warrant Or Right [Line Items]
Number of Warrants	22,253
Exercise Price	$ 5.68
Expiration Date	Mar. 30, 2022
Former Financial Advisor \| Warrant Three
Class Of Warrant Or Right [Line Items]
Number of Warrants	17,066
Exercise Price	$ 12.60
Expiration Date	Jun. 30, 2022
Former Financial Advisor \| Warrant Four
Class Of Warrant Or Right [Line Items]
Number of Warrants	14,286
Exercise Price	$ 12.60
Expiration Date	Aug. 31, 2022

Restructuring Charges and Other Severance Related Charges - Additional Information (Details)				1 Months Ended	12 Months Ended
	Oct. 01, 2019 USD ($)	Jul. 31, 2019 USD ($)	May 29, 2019 USD ($)	Jun. 30, 2019 Employee	Dec. 31, 2019 USD ($)
Restructuring Cost And Reserve [Line Items]
Accrued liabilities in connection with remaining unpaid obligations					$ 25,000
Employee Severance
Restructuring Cost And Reserve [Line Items]
Severance and other costs settled in cash			$ 1,050,000
Number of employees terminated \| Employee				32
Employee Severance \| Frank Amato
Restructuring Cost And Reserve [Line Items]
Severance payment	$ 800,000
Restructuring charge including accelerated stock-based compensation expense					$ 800,000
Employee Severance \| Former Officer
Restructuring Cost And Reserve [Line Items]
Severance payment		$ 147,500

Subsequent Events - Additional Information (Details)	Mar. 27, 2020 USD ($) shares	Mar. 26, 2020 Director	Dec. 31, 2019 shares	Dec. 31, 2018 shares
Subsequent Event [Line Items]
Common stock, shares issued			29,835,183	29,450,035
Subsequent Event
Subsequent Event [Line Items]
Number of board of directors \| Director		3
Stock Purchase Agreement \| Subsequent Event \| Lincoln Park
Subsequent Event [Line Items]
Value of shares issued \| $	$ 5,000,000
Common stock, shares issued	461,676
Stock Purchase Agreement \| Subsequent Event \| Lincoln Park \| Maximum
Subsequent Event [Line Items]
Value of shares issued \| $	$ 25,000,000
Additional commitment shares issued on pro-rata	230,838